Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell (e.g., honey, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424130100 - IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424174100 Cancer cell 207
424173100 Hematopoietic cell 137
Entries
DocumentTitleDate
20130071407METHODS FOR MODULATING HEMATOPOIESIS AND VASCULAR GROWTH - This application pertains to methods and compositions that modulate proliferation and/or differentiation of undifferentiated mesodermally-derived cells so as to have an effect on at least one of vascular growth and hematopoiesis.03-21-2013
20110206699Methods for the Treatment of Graft-Versus-Host Disease - Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject.08-25-2011
20090123482ASSAYS FOR DETERMINING COMPOUNDS WHICH MODULATE TRAM PHOSPHORYLATION - Disclosed are assays for the determination and quantification of the phosphorylation of TRAM (Trif-related adaptor molecule). TRAM is rapidly phosphorylated upon LPS stimulation by protein kinase C epsilon (PKCε) and that this phosphorylation is vital for TRAM to function normally. Assays suitable for detecting the state of phosphorylation of TRAM have utility in identifying compounds which have activity in modulating TRAM. Further disclosed are compounds which have utility in modulating the phosphorylation of TRAM to modulate signalling mediating by the Toll Like Receptor 4 (TLR4) receptor.05-14-2009
20090196878Intestinal epithelial glucose sensor - The present invention relates to a mammalian intestinal epithelial glucose sensor; more specifically to a human intestinal epithelial glucose sensor. The invention relates further to the use of this sensor to modulate or monitor intestinal carbohydrate uptake and metabolism and to the use of ligands and/or inhibitors and/or activators of this sensor to treat or prevent diseases such as diabetes and obesity, and to provide nutritional aids for the elderly, infants and athletes.08-06-2009
20130183320ANTI-LRP5 ANTIBODIES AND METHODS OF USE - The invention provides anti-LRP5 antibodies and methods of making and using the same.07-18-2013
20120171225Diagnostic Method for Predicting the Risk of Cancer Recurrence Based on Histone Macroh2A Isoforms - The present invention relates to a method for diagnosing the risk of cancer recurrence in a mammalian patient, comprising detecting the expression of macroH2A1.1 and/or macroH2A2 in a biological sample obtained from said patient, wherein a low or reduced expression of said macroH2A1.1 and/or macroH2A2 is indicative for an increased risk of cancer recurrence in said patient. The present invention is further directed at improved methods for treating cancer, in particular breast and/or lung cancer, based on said diagnostic method.07-05-2012
20100055113CELLULAR RECEPTOR FOR ANTIPROLIFERATIVE FACTOR - The present invention concerns the receptor for antiproliferative factor (APF) from bladder epithelial cells. In particular, there are compositions and methods for modulating APF, APF receptor, and/or the binding of APF to APF receptor. Agents that interfere with the binding of APF to its receptor or agents that enhance the binding of APF to its receptor are contemplated. In specific aspects, certain compositions are employed for a therapeutic purpose, such as interstitial cystitis or cancer, for example.03-04-2010
20110189200METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS - The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of DII4 antagonists that block DII4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable DII4 antagonists for the invention include antibodies or antibody fragments that specifically bind DII4 and block DII4-Notch interactions, the extracellular domain of DII4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft-versus-host disease.08-04-2011
20080299135METHODS AND COMPOSITIONS FOR NERVE REGENERATION - Methods and compositions for modulating growth of a neuron with a Wnt, a Wnt-like substance, and/or a chemical compound affecting a Wnt signaling pathway are disclosed. Also disclosed are methods for identifying a substance that modulates growth of a neuron by obtaining a candidate substance and contacting the candidate substance with the neuron are disclosed and methods for modulating growth of a neuron in a subject using a Wnt, a Wnt-like substance, and/or a chemical compound affecting a Wnt signaling pathway. The Wnt, Wnt-like substance, and/or chemical compounds affecting a Wnt signaling pathway can be delivered to the subject using gene therapy techniques. Also disclosed are pharmaceutical compositions for modulating growth of a neuron in a mammal that include a Wnt or a Wnt-like substance. Methods and compositions for inhibiting growth of a neuron are also disclosed.12-04-2008
20110195076THERAPEUTIC AGENT - The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders.08-11-2011
20090191220METHODS FOR THE DIAGNOSIS AND TREATMENT OF CRITICALLY ILL PATIENTS WITH ENDOTHELIN, ENDOTHELIN AGONISTS AND ADRENOMEDULLIN ANTAGONISTS - The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.07-30-2009
20100150945ANTI-MDL-1 ANTIBODIES - Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis.06-17-2010
20100119525METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS - The present invention relates to a method for prolonging longevity using and NPC1L1 antagonist. The present invention also provides a method for reducing weight in an individual who consumes a high-fat diet using an NPC1L1 antagonist.05-13-2010
20100074907Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists - This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.03-25-2010
20120183564INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION - The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.07-19-2012
20120183563IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R07-19-2012
20120183562SECRETED FXYD PROTEINS EXPRESSED IN RESPONSE TO EPITHELIAL TISSUE DAMAGE, AND USES THEREFOR - Secreted FXYD family proteins are expressed by intestinal mucosa and/or associated tissues to regulate cell production in intestinal crypts in response to tissue damage. Such tissue damage may arise from disease, exposure to injurious chemicals (e.g., due to poisoning, chemotherapy, chemical weapons), or exposure to injurious radiation (e.g., due to nuclear power accidents, radiological weapons, radiation therapy). Because these proteins are secreted in response to epithelial tissue damage, some of them are implicated in tissue repair response or an inflammatory response which prolongs or exacerbates the tissue damage. Examples of these proteins include FXYD 3, FXYD 4, and FXYD 5. Diagnostic methods based upon the role of the FXYD proteins in epithelial tissue damage are disclosed. Also provided are antibodies raised against the FXYD family proteins, a kit for detecting at least an epitope of a polypeptide, a method of producing an antibody raised against an epitope of a polypeptide, and a method of diagnosing damage to an epithelial tissue.07-19-2012
20130034570METHODS AND COMPOSITIONS FOR MODULATING PROSTASIN - The invention provides methods and compositions related to modulating prostasin.02-07-2013
20130034567PROTEIN MODULATORS - The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma.02-07-2013
20130034566ANTI-CDH3 ANTIBODIES AND USES THEREOF - The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.02-07-2013
20130034569IL-18 RECEPTOR ANTIGEN BINDING PROTEINS - Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.02-07-2013
20130034568METHODS OF TREATING OR PREVENTING PERIODONTITIS AND DISEASES ASSOCIATED WITH PERIODONTITIS - The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.02-07-2013
20090258026ANTI-NOTCH1 NRR ANTIBODIES AND METHODS USING SAME - The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies. 10-15-2009
20120207770ANTIPROLIFERATIVE AGENT - The invention provides an antibody specific to the ANGPTL4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the C terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer. The antibody may be monoclonal and or humanized antibody.08-16-2012
20120207766INTRACELLULAR TOLL-LIKE RECEPTORS PATHWAYS AND AXONAL DEGENERATION - The present invention is directed to the identification of novel mechanisms involved in the initiation and spreading of axonal degeneration. In particular, the instant invention relates to the identification of a relationship between Toll-Like Receptors (TLRs) and axonal degeneration and the use of TLR inhibitors as antagonists of axonal degeneration.08-16-2012
20130039929METHOD TREATING BREAST CANCER - The present invention relates, in general, to breast cancer and, in particular, to methods of treating breast cancer comprising administering to a subject in need thereof an agent that modulates signal transduction regulated by β-arrestin (e.g., β-arrestin 1). The invention further relates to methods of identifying compounds suitable for use in such methods.02-14-2013
20130039928COMPOSITIONS AND METHODS FOR REVERSING CORTICOSTEROID RESISTANCE OR TREATING RESPIRATORY INFECTIONS - The present invention features methods for reversing corticosteroid resistance, as well as for the treatment of respiratory infections, particularly those associated with chronic obstructive pulmonary disease. In one embodiment, the method increases Nrf2 biological activity or expression.02-14-2013
20100098715ANNEXIN II COMPOSITIONS FOR TREATING OR MONITORING INFLAMMATION OR IMMUNE-MEDIATED DISORDERS - Methods and compositions for treating, detecting, diagnosing or assisting in the diagnosis of an inflammatory or immunological disorder are provided. The authors have made the novel discovery that anti-dsDNA antibodies are reactive to cell surface annexin II and through this interaction, anti-dsDNA antibodies are bound and then internalized and translocated into the cytoplasm and/or nucleus where they mediate altered cellular functions. Compositions that inhibit or interfere with the interaction of annexin II with anti-dsDNA antibodies can be used to treat one or more symptoms or pathological processes of an inflammatory or immunological disorder, preferably an auto-immune disorder. Methods for monitoring the progression or severity of an inflammatory or immunological disorder are also provided. In certain embodiments, levels of annexin II and/or anti-dsDNA antibodies, including anti-dsDNA antibodies that can bind to annexin II, are assessed and compared to a reference level of annexin II and/or anti-dsDNA antibodies that corresponds to a specific stage or severity of the disorder.04-22-2010
20100098711ANTAGONIST ANTIBODIES AGAINST EPHB3 - EphB 3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.04-22-2010
20120263735SYNTHETIC IMMUNOGENIC GLYCOCONJUGATE FOR MELANOMA IMMUNOTHERAPY - The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (I) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors overexpressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.10-18-2012
20100111974Treatment of Cachexia - The invention characterises and provides a receptor for Proteolysis Inducing Factor (PIF) and associated methods and materials employing the same. These have utility, for example, in the provision of treatments for cachexia.05-06-2010
20100111973METHODS FOR TREATING MICA-RELATED DISORDERS - Disclosed herein are materials and methods for treating cancer. In particular, the compositions and methods for treating cancers associated with MICA overexpression are provided.05-06-2010
20100111972Method for preventing or treating opiate tolerance and dependence - The present invention provides a method for preventing or treating opiate tolerance and dependence by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. The opiate tolerance and dependence can be caused by chronic morphine treatment and withdrawal. The blocking reagent can be an EphB receptor blocker such as EphB1-Fc and EphB2-Fc.05-06-2010
20100104584GENES INVOLVED IN MITOCHONDRIAL BIOGENESIS - The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate conditions associated with mitochondrial dysfunction. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat conditions associated with mitochondrial dysfunction.04-29-2010
20100104581Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions - The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described.04-29-2010
20100104583Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with anti-angiogenic antibodies or equivalent thereof, in combination with a pyrimidine based antimetabolite and a platinum-based alkylating agent based therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.04-29-2010
20100104582CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts - Disclosed are methods and compositions relating to CD200 and its receptor, CD200R which modulate bone mass via the differentiation of osteoclasts.04-29-2010
20100104585Methods and Reagents for Regulation of Cellular Responses in Biological Systems - Multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can function for binding or targeting to any biological particle or molecule and particularly to targeting of cells or cell types or viruses, for cell aggregation and for macromolecular assembly of biological macromolecules. The multivalent ligands of this invention are applicable for creating scaffolds (assemblies) of chemical or biological species, including without limitation, antigens, epitopes, ligand binding groups, ligands for cell receptors and various macromolecules. In these scaffolds, the number, spacing, relative positioning and relative orientation of recognition elements can be controlled. The invention also relates to methods for aggregating biological particles and macromolecules and for modulating biological response employing the multivalent ligands provided.04-29-2010
20100040637Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133) - Methods and compositions for detecting and treating diseases, especially cancer, and particularly breast, bladder, colon, gastrointestinal, kidney, liver, lung, melanoma, ovary, pancreatic, pharyngeal, prostate cancer and renal, associated with differential expression of prominin-1 (CD133) in disease cells compared to healthy cells. Also provided are antagonists or agonists of prominin-1, and methods for screening agents that modulate the prominin-1 level or activity in vivo or in vitro.02-18-2010
20100040636Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists - We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.02-18-2010
20100143381LYSOPHOSPHATIDIC ACID RECEPTOR TARGETING FOR LUNG DISEASE - The present invention contemplates that lysophosphatidic acid (LPA) may be induced by lung injury and may be responsible for aberrant wound-healing responses. For example, in a bleomycin model of pulmonary fibrosis LPAi deficient mice are protected from pulmonary fibrosis and mortality. Specifically, chemotactic-induced fibroblast responses, lung fibroblast accumulation, and vascular permeability increases were all attenuated. In contrast, however, bleomycin-induced leukocyte recruitment was preserved. These results demonstrate that LPAi activity may link pulmonary fibrosis with lung injury by mediating fibroblast recruitment and vascular leak. The present invention therefore represents LPAi as a new target to treat lung diseases including, but not limited to, fibrosis, idiopathic pulmonary fibrosis, and acute respiratory distress syndrome.06-10-2010
20130045216Method for Treating Amyloid Disease - Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (Aβ) or on dialysis of blood or plasma exchange in order to remove Aβ peptides from the blood circulation, and/or brain or other affected organs.02-21-2013
20130045217LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE - The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.02-21-2013
20100143384NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS - In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.06-10-2010
20090297536Compositions, kits, and methods for identification, assessment, prevention and therapy of cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer.12-03-2009
20100092488Method for Treatment or Prevention of Disease Associated Wtih Functional Disorder of Regulatory T Cell - The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.04-15-2010
20130028916ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.01-31-2013
20130028915DENDRITIC CELL (DC)-VACCINE THERAPY FOR PANCREATIC CANCER - Compositions and methods for eliciting therapeutic immunity and improving clinical outcomes in patients with pancreatic cancer are disclosed herein. The present invention describes a dendritic cell (DC)-vaccine comprising DCs pulsed with peptides derived from pancreatic cancer antigens for the therapy against pancreatic cancer. The vaccine described herein is safe, and leads to expansion of cancer specific T cells in patients with pancreatic cancer.01-31-2013
20130028914Antibodies that Bind Tau Oligomers - Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies.01-31-2013
20130089563METHOD OF DIAGNOSING AND TREATING CANCER - A method of diagnosing and treating a glioma or a breast cancer is disclosed. The method of diagnosing comprises analyzing an amount or activity of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) in a brain or breast cell sample of the subject, wherein an up-regulation in an amount or activity of hnRNP A2/B1 beyond a predetermined threshold with respect to a control cell sample is indicative of the breast cancer or glioma. The method may also be used for staging the cancer and for predicting patient's prognosis of survival. The method of treating glioblastoma and metastatic breast cancer includes inhibiting the expression and/or activity of hnRNP A2/B1.04-11-2013
20130089562METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS - Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.04-11-2013
20130052205FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS - The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.02-28-2013
20110002944Compositions and Methods to Promote Neural Cell Growth - The instant invention provides methods and compositions for promoting neural cell growth by inhibiting myelin associated glycoprotein (MAG)-induced inhibition of axonal regeneration. The invention relates to methods for identifying agents that inhibit MAG-induced inhibition of neural cell growth. Methods for inhibiting myelin associated glycoprotein (MAG)-induced inhibition of neural cell growth in a patient, methods for treating or preventing a MAG-induced disease or disorder of the CNS or PNS, comprising the step of administering at least one of the compositions according to this invention are provided. The invention includes kits comprising one or more agents identified according to the invention.01-06-2011
20090304713BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.12-10-2009
20090041784Compositions and methods relating to glucagon receptor antibodies - The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.02-12-2009
20090041783ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY - The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: 02-12-2009
20130071408Methods for Diagnosis and Treatment of Non-Insulin Dependent Diabetes Mellitus - Methods and compositions are provided for the treatment and diagnosis of diseases related to hyperglycemic conditions, including diabetes, insulin resistance, and the like. Genetic polymorphisms are shown to be associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to these conditions. The corresponding proteins are useful as targets for therapeutic intervention.03-21-2013
20130071411IAP BIR DOMAIN BINDING COMPOUNDS - Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II03-21-2013
20130071410Human CGRP Receptor Binding Proteins - Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related, disorders including the treatment and/or prevention of migraine headaches.03-21-2013
20130071409ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells - The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.03-21-2013
20090092622MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUSES - A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions.04-09-2009
20130058954DIAGNOSTIC AND THERAPEUTIC METHODS FOR CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY, KERATOCONUS OR PELLUCID DEGENERATION - The present invention relates to methods of diagnosis and treatment of corneal ectasia following refractive surgery, keratoconus or pellucid marginal degeneration in a subject by determining or modulating the level of expression of molecules associated with the Wnt signalling pathway. Marker molecules of the present invention include SFRP1, PITX2, LEF1, WNT16 and WNT5A.03-07-2013
20130058956EXTRACELLULAR IFI16 AS THERAPEUTIC AGENTS - The present invention relates to the inhibition of the circulating extracellular form of the interferon inducible protein 16 (extracellular IFI16) for the treatment of diseases, particularly autoimmune and/or inflammatory disorders or infective disorders.03-07-2013
20130058957DENDRITIC CELL IMMUNORECEPTOR AGONIST - An object of the present invention is to find a ligand for a DCIR and to search for an agonist and an antagonist for the DCIR.03-07-2013
20130058958COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS - The invention relates to use of certain compounds including, for example, certain charged amino acids and structural analogs thereof, for reducing the viscosity of aqueous protein-containing formulations. Associated compositions of matter and methods of use are also contemplated within the present invention.03-07-2013
20130058955ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE - The invention provides anti-polyubiquitin antibodies and methods of using the same.03-07-2013
20110014212Certain Chemical Entities, Compositions and Methods - Provided is a method of treating myasthenia gravis in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator, or a pharmaceutically acceptable salt thereof.01-20-2011
20090269360THERAPY - The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.10-29-2009
20090269359Method of Treatment and Prophylaxis of Diseases Related to Amyloid Deposition Using IGM - The invention relates to a method of treating or preventing disease associated with β-amyloid polypeptides comprising administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM), and pharmaceutical compositions comprising such preparations.10-29-2009
20090060924ANTI-SCLEROSTIN ANTIBODIES - Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.03-05-2009
20120225085DISPLAY OF DISULFIDE LINKED DIMERIC PROTEINS IN FILAMENTOUS PHAGE - Methods are provided for the display of a complex homodimer protein on the surface of a bacteriophage particle and combinatorial synthetic libraries of such proteins displayed as a fusion polypeptide with filamentous phage pIX coat protein. Heterodimeric or more complex interchain bonded structure, such as disulfide-linked, multimeric proteins, may be displayed using the method of the invention.09-06-2012
20120225084KLF FAMILY MEMBERS REGULATE INTRINSIC AXON REGENERATION ABILITY - This invention relates, e.g., to a method for promoting CNS axon regeneration, comprising (1) inhibiting the expression or activity in a neuron of one or more of the members of the Krüppel-like transcription factor (KLF) family that suppress axon growth (e.g., KLF 1, 2, 3, 4, 5, 9, 12, 13, 14, 15 and/or 16), and/or (2) stimulating the expression or activity in a neuron of one or more of the members of the KLF family that promote axon growth (e.g., KLF 6 and/or 7).09-06-2012
20130064837INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY - The present invention relates to ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.03-14-2013
20130064836Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.03-14-2013
20130064835RAGE REGULATES ROCK ACTIVITY IN CARDIOVASCULAR DISEASE - A method is provided for treating a RAGE-related disorder in a subject afflicted therewith comprising administering to the subject a therapeutically effective amount of an antagonist of rho-associated protein kinase 1 (ROCK1) so as to thereby treat the RAGE-related disorder. A method is also provided for treating a ROCK1-related disorder in a subject afflicted therewith comprising administering to the subject therapeutically effective amount of antagonist of receptor for advanced glycation end products (RAGE) so as to thereby treat the ROCK-related disorder.03-14-2013
20090238837High Affinity Siglec Ligands - The invention relates to high affinity Siglec ligands that are useful for isolating cells that express Siglecs and for delivering agents to cells that express Siglecs. In one embodiment, the invention provides a method for treating cancer in a mammal that involves administering a Siglec ligand of the invention to the mammal, where the Siglec ligand is linked to a therapeutic agent.09-24-2009
20110045003CADHERIN-11 ANTAGONISTS AND METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISORDERS - The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.02-24-2011
20090047294Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration - The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and/or treatment of skeletal muscle degeneration.02-19-2009
20120114665HUMAN ANTIBODIES TO HUMAN RANKL - Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.05-10-2012
20090010943Peptides associated with HLA-DR MHC class II molecule and involved in Rheumatoid arthritis - Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with Rheumatoid Arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of Rheumatoid Arthritis.01-08-2009
20100086557Pharmaceutical composition for tumor treatment - The present invention provides pharmaceutical compositions for use in tumor therapy as well as a medical treatment in tumor therapy. The compositions comprise a leukocyte diminishing and/or leukocyte inactivating agent for use in bacterial tumor therapy in combination. Preferably, the leukocyte inactivating or diminishing agents are expressed by the bacteria used for the production of a pharmaceutical composition for bacterial tumor therapy.04-08-2010
20080305117Kir-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.12-11-2008
20080305116Anti-Cd154 Antibodies - The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.12-11-2008
20120237530INTEGRIN ALPHA 8-BETA 1-SPECIFIC MONOCLONAL ANTIBODY - [Object] To obtain an anti-integrin α8β1 antibody which binds to integrin α8β1 derived from mammals of different species. Also, to obtain an anti-integrin α8β1 antibody which inhibits binding between integrin α8β1 and its ligand.09-20-2012
20120237529DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.09-20-2012
20080299132Synergistic compositions for treating HIV-1 - Synergistic pharmaceutical compositions for treating or preventing HIV-1 infections comprising anti-CCR5 monoclonal antibodies and CCR5 antagonists, viral fusion inhibitors or viral attachment inhibitors are disclosed. The compositions exhibit significant greater activity than is anticipated from the activity of either component alone. Also provided are methods for treating or preventing HIV-1 using the same.12-04-2008
20120237528Human Tissue Factor Antibody and Uses Thereof - The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.09-20-2012
20100034833HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-18 RECEPTOR - An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18Rα), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.02-11-2010
20110020368TREATING CANCER BY DOWN-REGULATING FRIZZLED-4 AND/OR FRIZZLED-1 - The present invention relates to a method for treating cancer, for instance breast cancer, in a subject by inhibiting Frizzled-4 and/or Frizzled-1 by administering to said subject a therapeutically effective amount of a modulator of Frizzled-4 and/or Frizzled-1, for example a specific antibody or a siRNA.01-27-2011
20100226929Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.09-09-2010
20090098146METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION - Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β04-16-2009
20110142857METHODS OF ALTERING PERIPHERAL B CELL POPULATIONS AND USES THEREOF - A method of altering peripheral B cell populations in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of depleting peripheral B cells in the subject, and wherein the subject does not have a hematologic cancer or an autoimmune disease, thereby altering the peripheral B cell populations in the subject.06-16-2011
20090053238Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations - The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin α02-26-2009
20100330101BIFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION - A bifunctional composition comprising an intracellularly effective immunomodulating nucleic acid component containing at least one immunostimulatory, immunoinhibitory or immunomodulating motif and selected from a mononucleotide, a dinucleotide, an oligonucleotide or a polynucleotide with either a natural phosphodiester backbone or a modified backbone, optionally in combination with a specific antigen, in association with a protein binding to specific receptors on mammalian cell surfaces selected from the group consisting of cholera toxin (CT), the subunit B of CT (CTB), 12-30-2010
20090202566Use of the ENDO-180 gene and polypeptide for diagnosis and treatment - This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO180 modulators in treatment of disease.08-13-2009
20100297148CD38 MODULATED CHEMOTAXIS - The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, 11-25-2010
20080274124Ligand for G-protein coupled receptor GPR72 and uses thereof - The present invention relates to methods, reagents and kits for detecting of GPR72 polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against GPR72. It further relates to substances for preventing, treating and/or alleviating diseases or disorders characterized by dysregulation of GPR72 polypeptide signalling.11-06-2008
20090068200Method for Prongf Assay for in Vitro Diagnosis of Cancer in Particular Breast, Thyroid or Lung Cancer, and Therapeutic Use of Prongf - The present invention concerns a method for in vitro diagnosis of cancer, in particular breast, thyroid or lung cancer, which consists in determining the presence of ProNGF in a biological sample derived from a patient suspected of suffering from cancer, in particular breast, thyroid or lung cancer. Said method may be used for early diagnosis, screening, therapeutic follow-up, prognosis and for diagnosing relapses in cancer and in particular breast, thyroid or lung cancer.03-12-2009
20090311271Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1) - The present invention provides methods of selectively inhibiting the binding of one ligand for LOX-1, but not one other ligand for LOX-1. Moreover, the invention relates to the identification of binding partners that act in a selective manner to inhibit the binding of one ligand to LOX-1, but not one other ligand for LOX-1, and methods of identifying such binding partners. Pharmaceutical compositions comprising the binding partners for LOX-1, in particular, anti-LOX-1 antibodies or fragments thereof, are also provided in the present invention.12-17-2009
20100196398TARGETED BINDING AGENTS DIRECTED TO CD105 AND USES THEREOF - The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of CD105 and as diagnostics.08-05-2010
20100143383OXGR1 AGONISTS FOR USE IN THERAPIES FOR METABOLIC DISORDERS - Methods for identifying OXGR1 modulator useful for the treatment of diabetes and conditions associated with diabetes are provided. Further provided are methods for treating diabetes and conditions associated with diabetes with an OXGR1 agonist.06-10-2010
20110287029INHIBITION OF THE BETA3 SUBUNIT OF L-TYPE CA2+ CHANNELS - The present invention provides reagents and methods for identifying inhibitors of the L-type Ca11-24-2011
20110129483Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy - The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.06-02-2011
20090081237Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents - Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention identifies and characterizes the FANCI polypeptide as a vital component of the Fanconi anemia pathway and discloses inhibitors of FANCI and methods of using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.03-26-2009
20110287030COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.11-24-2011
20130216557LTBR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS - The invention provides compositions and methods for predicting therapeutic responsiveness of a subject having an autoimmune disorder to an agent that inhibits signaling via LTβR based on the level of expression of IFN or a marker thereof in the subject. The invention also provides methods of treating selected subjects with agents that inhibit or reduce signaling vial LTβR.08-22-2013
20100221261IAP BIR DOMAIN BINDING COMPOUNDS - Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II09-02-2010
20110293636Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.12-01-2011
20110293634ANTIBODIES BINDING TO ADRENOMEDULLIN RECEPTORS AND USES THEREOF AS DRUGS - The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug.12-01-2011
20110293632POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.12-01-2011
20110293633PREPARATION USEFUL FOR, AND METHOD FOR TREATMENT OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIC PURPURA (NAIT) - A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 12-01-2011
20100196399LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions - LDL receptor-related proteins 1 and 2 (LRP-1 and LRP-2) and interaction between lactoferrin and LRP-1, LRP-2, or p42/44 MAP kinase in diagnosis and treatment of disorders such as bone or cartilage disorders. Also disclosed are methods of screening for related therapeutic compounds.08-05-2010
20100166776COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS - The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).07-01-2010
20090117132Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment - The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g, at any stage of the cancer).05-07-2009
20110300159Sulfonated Sclerostin, antibodies, epitopes and methods for identification and use therefor - Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds whichh disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.12-08-2011
20110300161Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma - The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.12-08-2011
20090130124Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration - The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention further provides methods for isolating hematopoietic progenitor cells.05-21-2009
20090136520MITOCHONDRIAL LOCALIZATION OF MUC1 - The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either or both of HSP70 and HSP90. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction.05-28-2009
20100034831Agents that Bind a Target in Pulmonary Tissue for Targeting Respiratory Diseases - Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.02-11-2010
20120189641COMBINATION ANTI-CANCER THERAPY - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906). The present invention also provides a pharmaceutical composition comprising either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906), with a pharmaceutically acceptable carrier.07-26-2012
20110217317TREATMENT OF THROMBOCYTOPENIA - The present invention relates to treatment of thrombocytopenia with a pharmaceutical composition comprising re-combinant polyclonal anti-RhesusD antibody product as the active ingredient.09-08-2011
20110217318ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY - The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: 09-08-2011
20110217314Methods and Compositions for Modulating Apoptosis - This invention relates to compositions and methods for modulating apoptosis by regulating the activity of endoplasmic reticulum transmembrane glucose regulated protein 78 (GRP78).09-08-2011
20110217313TREATMENT OF ORTHOPEDIC CONDITIONS - Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorder, disease, or condition, and promoting post-surgical wound-healing.09-08-2011
20100021478DIAGNOSTIC ANTIBODY ASSAY - The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.01-28-2010
20080241167CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION - The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.10-02-2008
20110171241Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.07-14-2011
20090317405ANTIBODY AND USES THEREOF - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis. 12-24-2009
20100111975Monoclonal Antibodies for Treatment of Cancer - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.05-06-2010
20100266616POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.10-21-2010
20100034832METHODS FOR MANIPULATING STEM CELLS - The invention generally features methods and compositions for enhancing stem cell function. In particular, the invention provides therapeutic or prophylactic methods that can increase survival, growth or proliferation during blood and/or stem cell transplant and protect stem cells in settings of injury.02-11-2010
20110171240USE OF CCR9, CCL25/TECK, AND INTEGRIN ALPHA4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE - The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified.07-14-2011
20100266615D1-1 NUCLEIC ACIDS, POLYPEPTIDES AND RELATED METHODS - The disclosure provides, among other things, novel angiogenesis-related nucleic acids, polypeptides and methods of use.10-21-2010
20100266617ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 - Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.10-21-2010
20100285034METHOD - Described are methods of separating viable cells, apoptotic cells and dead cells and antibodies or use in such methods. The antibodies may also be used in treatment of inflammatory disease, cancer and in wound healing.11-11-2010
20100119526DLL4 Signaling Inhibitors and Uses Thereof - DLL4-binding antibodies, specifically antibodies preventing Notch signaling and internalization of DLL4, can: more efficiently than inhibitors only preventing DLL4-mediated Notch-signaling disrupt angiogenesis and pathological processes including tumor growth.05-13-2010
20080267975Mer Diagnostic and Therapeutic Agents - Mer diagnostic and therapeutic agents are disclosed. The agents are useful in the diagnosis and treatment of a variety of diseases including leukemia, lymphoma, and clotting disorders.10-30-2008
20100098713NOVEL 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 AND 65577 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.04-22-2010
20100098714Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy - Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.04-22-2010
20120107329EGFR and PAR2 Regulation of Intestinal Permeability - The present invention provides methods for diagnosing and treating an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR05-03-2012
20120107328GAMMA SECRETASE MODULATORS - This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).05-03-2012
20090263403MAMMALIAN CELL MEMBRANE PROTEINS; RELATED REAGENTS - The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.10-22-2009
20110200618ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS - This invention relates to treatment of neuro-psychiatricdisorders. Specifically, the invention relates to the use of small molecule agent specific against erbB4, erbB3 or their combination, or fragments thereof in inhibiting the attachment of erbB4, erbB3 or their combination to NRG1.08-18-2011
20110200617COMBINATION THERAPY OF BETA-GLYCOLIPIDS AND ANTIBODIES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS - The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphingolipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immuno-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 anti-body (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.08-18-2011
20090274709Lipocalin-2 As A Prognostic and Diagnostic Marker For Heart And Stroke Risks - Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascular diseases.11-05-2009
20100272738ANTI-OX40L ANTIBODIES AND METHODS USING SAME - The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.10-28-2010
20130216556ANTIBODY FORMULATIONS - Formulations of anti-VLA-1 antibodies are described.08-22-2013
20110171239pH INDUCED SILK GELS AND USES THEREOF - This invention provides for compositions, methods and devices for rapidly converting silk fibroin solution into a silk fibroin gel using direct application of voltage, in a process called electrogelation. The silk fibroin gel may be reversibly converted back to liquid form by applying reverse voltage or may be converted further to β-sheet structure by applying shear force or other treatments. The electrogelated silk may be used as an extracted bulk gel, spray or stream of gel for processing into materials or devices, or may be used as silk gel coating to devices. Active agents may be embedded in the silk gel for various medical applications. This invention also provides for methods and compositions for preparing adhesive silk pH-gels. For example, the method comprises reducing pH level of a silk fibroin solution to increase the bulk or local proton concentration of the silk fibroin solution, thereby forming adhesive silk gels.07-14-2011
20090104209METHODS OF REDUCING A VIRAL INFECTION AND KITS THEREFORE - A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore.04-23-2009
20080213288Combined Use Of A Modulator Of CD3 And A GLP-1 Compound - Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.09-04-2008
20100221262ANTI-UNC5B ANTIBODIES AND METHODS OF USE - The invention provides anti-Unc5B antibodies, compositions and kits comprising the antibodies and methods of making and using the antibodies. The present invention also relates to use of anti-Unc5B antibodies to modulate angiogenesis and to treat or prevent disorders associated with abnormal angiogenesis.09-02-2010
20100285035High Affinity Antibody Antagonists of Interleukin-13 Receptor Alpha 1 - High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.11-11-2010
20090169569APO-2L receptor agonist and CPT-11 synergism - Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.07-02-2009
20080241168Transmembrane protein amigo and uses thereof - The present invention provides methods and compositions relating to vertebrate AMIGO, AMIGO2, AMIGO3, collectively vertebrate AMIGO polypeptides, related nucleic acids, and polypeptide domains thereof having vertebrate AMIGO-specific structure and activity, and modulators of vertebrate AMIGO function.10-02-2008
20080241166Ligands that bind a receptor - The invention relates to ligands, such as immunoglobulin single variable domains, that have binding specificity for a receptor. Preferably the receptor is a cell surface receptor and/or the ligand inhibits the activity of the receptor.10-02-2008
20110206698ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.08-25-2011
20090035321Intercellular adhesion molecules and their binding ligands - The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.02-05-2009
20090035322Human Antibodies to Human CD20 and Method of Using Thereof - A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.02-05-2009
20080274122Plks as Modifiers of the Beta Catenin Pathway and Methods of Use - Human PLK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PLK are provided.11-06-2008
20080274123Specific Binding Members Against Synaptophysin - The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and/or an antibody VL domain selected front the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated it liver fibrosis.11-06-2008
20080279864High Throughput Screen Utilizing Newly Discovered Intramolecular Neuronal Calcium Channel Interactions To Discover New Analgesics - The present invention relates to compositions to treat Ca11-13-2008
20080279865Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy - The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody, or an antigen-binding portion thereof, particularly a human antibody to human CTLA4, e.g., antibody 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also known as 11.2.1), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also known as MDX-010 and 10D1), in combination with hormonal therapy. Hormonal therapy agents include, inter alia, an anti-androgen (e.g., megestrol, cyproterone, flutamide, nilutamide, and bicalutamide), a GnRH antagonist (e.g., abarelix and histrelin), and a LH-RH agonist (e.g., leuprolide, goserelin, and buserelin). The invention relates to neoadjuvant therapy, adjuvant therapy, therapy for rising PSA, first-line therapy, second-line therapy, and third-line therapy of prostate cancer, whether localized or metastasized.11-13-2008
20080286287Methods and Agents for Modulating Cellular Activity - The present invention discloses the use of modified IGFBP-2 and agents that regulate the interaction between HBD of IGFBP-2 and EC or PC matrix components to prevent cellular proliferation invasion and/or migration (metastases).11-20-2008
20080286289Use of B Cell Expansion Agents in Generating Antibodies - A method for efficiently generating antibodies immunizes an animal with a target antigen and a B cell expansion agent, such as an anti-CD40 agonist. The antibodies generated from this method are useful as therapeutic agents, diagnostic agents or research reagents in a variety of diseases and conditions.11-20-2008
20080292641Antigenic GM-CSF peptides and antibodies to GM-CSF - Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.11-27-2008
20100291107HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.11-18-2010
20100291105AGENT FOR THE TREATMENT OF MALIGNANT DISEASES - The invention proposes an agent for the treatment of tumor diseases, for example the multiple myeloma, said agent acting upon NK cells through the activation of an anti-tumor immune response after stimulation of the NKp30 receptor and the natural cytotoxicity receptors (NCR). Said agent contains in an acceptable carrier material a physiologically effective amount of the BAT3 protein and/or BAT3/antiCD138 or BAT3-specific antibodies or derivatives of these substances. According to the principle identical to that adopted for the BAT3/anti-CD138 protein the invention may also be used for the treatment of CD138-negative tumors. For this purpose the antiCD138 component with an antibody fragment is replaced by an optional tumor antigen and the respective agent is used for the therapy of tumors expressing this tumor antigen. Moreover, the invention also proposes the use of recombinant BAT3 protein or a BAT3 fragment without anti-body-based fusion component for the treatment of malignant diseases by activating NKp30 and NCR on NK cells. Finally, the invention relates to the use of BAT3 cDNA for in-vivo and/or ex-vivo introduction of BAT3 into tumor cells leading to an improved detection by NK cells in the immunotherapy of malignant diseases.11-18-2010
20080199481COMPOUNDS - The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.08-21-2008
20120294871MODULATION OF GPCR-MEDIATED CAMP PRODUCTION THROUGH LRP6 AND ITS THERAPEUTIC APPLICATION - The present invention relates to low-density lipoprotein receptor related protein 6 (LRP6). More specifically, the present invention relates to targeting of LRP6 to modulate Gα11-22-2012
20080233131Vaccine - The invention provides a method for generating anti-CD4 auto-antibodies comprising administering to an individual an anti-CD4 antibody molecule which has a low affinity for native CD4 in said individual or a protein or peptide comprising a CD4-like epitope, wherein administration of said antibody molecule, protein or peptide results in the generation of anti-CD4 auto-antibodies.09-25-2008
20120045458USE OF NOTCH REGULATORS FOR MODULATING THE IMMUNE RESPONSE BY INDUCTION/SUPPRESSION OF INTERLEUKIN-22 - The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates to the use of modulating the immune response, primarily in case of infection reactions. The invention in particular relates to the use for treating illnesses associated with infections. The invention further relates to the use for reducing IL-22 production in T-cells.02-23-2012
20080286288Vascular endothelial growth factor 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.11-20-2008
20100143379MIF AGONISTS AND ANTAGONIST AND THERAPEUTIC USES THEREOF - The present invention relates to methods and compositions for selecting a subject for treatment with an agonist or antagonist of macrophage migration inhibitory factor (MIF), identifying a subject at risk for developing a disease associated with high or low MIF expression, predicting the severity of a disease associated with high or low MIF expression in a subject, and for predicting whether a subject is susceptible to a disease associated with high or low MIF expression. The invention also provides novel methods of diagnosing a patient for a disease associated with high or low MIF expression. Also provided are methods for treating a subject having a disease or disorder associated with high or low MIF expression.06-10-2010
20100143380COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION - The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual. In another embodiment, the invention is directed to methods of inhibiting choroidal neovascularization in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the agent inhibits choroidal neovascularization in the individual.06-10-2010
20100189722ANTI CD37 ANTIBODIES - Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.07-29-2010
20080213287Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell - A method of inhibiting infection by Flaviviridae viruses including HCV, GBC/HGV, and BVD in addition to VSV and any other virus capable of forming a complex with a lipoprotein strategies: preventing formation of a complex should one form, altering the conformation of such a complex to prevent its interaction with the cell receptor, blocking the cell receptor for the complex using an antibody to the receptor, blocking binding of the lipoprotein complex to the cell receptor using soluble lipoprotein receptor or fragments thereof, or downregulating the LDL receptor activity of the cells.09-04-2008
20090304714IKKi Inhibitor Therapies and Screening Methods, and Related IKKi Diagnostics - The present invention provides diagnostics, screening methods, and treatment methods related to obesity, insulin resistance, diabetes, weight loss, and related disorders. In particular, the present invention provides methods of treating such conditions with IKKi inhibitors, methods of diagnosing such conditions based on IKKi status, and methods of screening candidate IKKi inhibitors.12-10-2009
20090304712Neuronal Cell Death Inhibitor and Screening Method - A neuronal cell death inhibitor comprising a compound having an inhibitory activity on the production and/or release of glutamic acid in a microglia; by inhibiting the production and/or release in a microglia, neurite bead-like degeneration or neuronal cell death can be inhibited.12-10-2009
20110014213HUMAN ANTI-ALPHA 9 INTEGRIN ANTIBODY - The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-α9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.01-20-2011
20110206697SPINK1 TARGETED THERAPY - The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to SPINK1 as a clinical target for prostate cancer.08-25-2011
20090053241PDGFRbeta-specific inhibitors - The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.02-26-2009
20110206696METHODS FOR INHIBITING BONE LOSS AND BONE METASTASIS - The invention encompasses methods of inhibiting bone loss and bone metastasis.08-25-2011
20110206695ANTIBODIES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PROSTATE CANCER - XMRV appears to be related to both prostate cancer if it infects a male germ cell and chronic fatigue syndrome in both sexes. (If the virus does not infect a germ cell). Prostate cancer cells exhibit TSG101 on the surface only upon infection with a virus like XMRV. Antibodies to TSG101 can be effective diagnostics to identify individuals with a predisposition to prostate. They can also be used in place of current diagnostics to confirm the presence of prostate cancer. TSG101 antibodies, when administered in vivo, exhibit the ability to reduce tumor size, suppress metastatic transformation and extend survival.08-25-2011
20090028876METHODS OF MODIFYING CD11C+ DENDRITIC CELL DEVELOPMENT TO FORM OSTEOCLASTS FUNCTIONAL IN THE BONE ENVIRONMENT - An ex vivo method of producing osteoclasts is described that includes providing isolated CD 11 C01-29-2009
20090028875USE OF GILZ PROTEIN EXPRESSED IN DENDRITIC CELLS TO MODULATE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections.01-29-2009
20090028874Synthetic Protein as Tumor-Specific Vaccine - The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a fully synthetic vaccine. The invention is illustrated mainly by using HPV protein directed immunity as a model.01-29-2009
20110223179METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition.09-15-2011
20090162381Method for Treating Vascular Disorders - The invention relates to a method for identifying substances with antiapoptotic activity, where06-25-2009
20120231017HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I09-13-2012
20090162380Multispecific binding molecules comprising connecting peptides - The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.06-25-2009
20120070449METHODS OF TREATING INFLAMMATION - A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.03-22-2012
20120070448ANTI-IL-3RA ANTIBODY FOR USE IN TREATMENT OF BLOOD TUMOR - The present invention provides an antibody to human IL-3Rα chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3Rα chain but does not bind to C domain of the human IL-3Rα chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3Rα as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3Rα antibody as an active ingredient.03-22-2012
20090186039NOVEL USE OF GRP 94 IN VIRUS INFECTION - A novel use of GRP 94 in treatment of virus infection is provided. More specifically, a method of inhibiting virus infection by inhibiting expression of GRP 94 and/or inactivating activity of GRP 94, and a method of developing drugs for preventing and/or treating virus infection and/or diseases caused by virus infection by using GRP 94 as a target are provided.07-23-2009
20080317763Regulation of Metalloprotease Cleavage of Cell Surface Proteins - Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is prevented when critical residues within the pocket are changed. This provides use of the surface pocket within the extracellular domain of ADAM10, and the corresponding structure in related proteases such as ADAM17, as a target for structure-based computational and high-throughput screens for small-molecule substrate-specific inhibitors or monoclonal antibodies that inhibit ADAM protease cleavage of ephrins and other ADAM10 or ADAM17 substrates. These inhibitors will be useful in therapeutic intervention of tumour development, invasion and metastasis and other diseases which involve the activity of the ADAM10 and ADAM17 proteases, such as inflammation, cardio-vascular disease, arthritis and other auto-immune diseases.12-25-2008
20090252747NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 282P1G3 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.10-08-2009
20130122019ANTI-HUMAN ALPHA9 INTEGRIN ANTIBODY AND USE THEREOF - The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.05-16-2013
20090324614FC RECEPTOR BINDING PROTEINS - This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.12-31-2009
20090053239ACACS As Modifiers of the IGF Pathway and Methods of Use - Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.02-26-2009
20090053240Novel Immunoglobulin Insertions, Deletions and Substitutions - An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.02-26-2009
20090098145METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY - Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. Provided are methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.04-16-2009
20090081238Anti-notch1 NRR antibodies and methods using same - The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.03-26-2009
20110229494TENEURIN AND CANCER - The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.09-22-2011
20110229493NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING CANCER - The invention provides neuregulin antagonists and methods of using the neuregulin antagonists in delaying the time to tumor recurrence or preventing resistance of cancer cells to treatment with a therapeutic agent.09-22-2011
20110229491MINICHROMOSOME MAINTENANCE COMPLEX INTERACTING PROTEIN INVOLVED IN CANCER - The present invention relates to a protein that is interacting with the minichromosome maintenance complex in eukaryotes. More specifically, the invention relates to the use of a protein, interacting with the minichromosome complex, and the gene encoding this protein in diagnosis, prognosis and treatment of cancer.09-22-2011
20100297147COMPOSITIONS AND METHODS FOR MODULATING TLR14 ACTIVITY - Methods and compositions for modulating neural cell function using antagonists of TLR14 are disclosed. In particular, methods for treating, preventing and/or diagnosing TLR14-associated neurodegenerative conditions and/or disorders are disclosed. Screening methods for evaluating TLR14 modulators, e.g., agonists and antagonists, are also disclosed.11-25-2010
20090208513Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions - The present invention provides for methods and kits for detecting sepsis, trauma/hemorrhage or inflammation in a subject. It is based, at least in part, on the discovery that Augmenter of Liver Regeneration (“ALR”) is an early marker of these conditions. Accordingly, in other embodiments, the present invention provides for a method of treating sepsis, traumatic/hemorrhagic shock and inflammation by inhibiting ALR.08-20-2009
20090004207Methods and Compositions for Inhibiting Pathological Angiogenesis in the Eye - Disclosed herein are compositions and methods for inhibiting abnormal angiogenesis in the eye, particularly in the retina. The methods include administering to subject in need of treatment for pathological angiogenesis of the eye a pharmaceutically effective amount of an inhibitor of the receptor activity of the S1P2 receptor. Also included are compositions including an S1P2 receptor antagonist and an opthalmically acceptable excipient.01-01-2009
20090004206Polynucleotides and Polypeptide Sequences Involved in the Process of Bone Remodeling - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.01-01-2009
20090004205Prospective identification and characterization of breast cancer stem cells - A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.01-01-2009
20090220526ACUTE RENAL INJURY - We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and/or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage.09-03-2009
20090232832Polyclonal antiserum against a universal tumor antigen - The present invention relates to a polyclonal antiserum against a universal tumor antigen obtainable by (i) eliciting an in vivo humoral response against embryonic tissue in a non-human vertebrate, whereby said embryonic tissue is of the same genetic line as the non-human vertebrate; (ii) recovering from the immunized non-human animal spleen and isolating from said spleen individual spleen cells/lymphocytes; (iii) eliciting a second in vivo humoral response to the isolated spleen cells/lymphocytes suspension obtained in step (ii) in a further non-human animal of the same genetic line as the non-human animal of step (i); and (iv) isolating the desired polyclonal antiserum from said animal. Furthermore, the invention provides for the use of the polyclonal antiserum for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of cancer, in particular cancer of the breast, lung, prostate, uterus, colon, stomach or bladder. Additionally the invention relates to the use of the polyclonal serum of the invention for the preparation of a pharmaceutical composition, wherein said pharmaceutical composition is to be administered to a subject in need of treatment in combination with a further anti-proliferative drug or medicament.09-17-2009
20080260754COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.10-23-2008
20100015163DENDRITIC CELL POTENTIATION - A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.01-21-2010
20120195913COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.08-02-2012
20100183629ANTAGONISTS OF ENDOTHELIAL DIFFERENTIATION GENE SUBFAMILY 3 (EDG-3, S1P3) RECEPTORS FOR PREVENTION AND TREATMENT OF OCULAR DISORDERS - Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.07-22-2010
20100260779METHODS AND MOLECULES FOR MODULATING AN IMMUNE RESPONSE - A molecule capable of potentiating immune responses and modifying existing states of immune responsiveness is described. Also described are compositions containing the molecule, as well as methods for using the molecule and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.10-14-2010
20100260782NOVEL ANTI- Alpha 5 Beta 1 ANTIBODIES AND USES THEREOF - The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.10-14-2010
20100260781TREATMENT METHODS FOR AUTOIMMUNE DISORDERS - The present invention provides methods and compositions for expanding T regulatory cells ex vivo or in vivo using one or more SAP agonists. The methods and compositions are useful in the treatment of autoimmune diseases and in preventing foreign graft rejection.10-14-2010
20100260783Antibody Specific Binding to A Beta Oligomer and the Use - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.10-14-2010
20100260780Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.10-14-2010
20100150944METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND ANXIETY - The present invention relates to identification of cellular components, genotypes and gene expression profiles associated with mood disorders. In some embodiments, the present invention relates to the correlation between ribosomal protein S6 (RPS6) and depression and/or anxiety. Embodiments of the present invention further relate to regulation of the activity of RPS6, e.g., by p90 Ribosomal S6 protein kinase. Embodiments of the present invention provide methods and compositions for, e.g., diagnosing, treating, and monitoring depression and/or anxiety, or risk thereof, and for selecting, monitoring, and tailoring treatments for depression and/or anxiety.06-17-2010
20120195915IAP BIR domain binding compounds - Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I:08-02-2012
20120195914ALDOSTERONE INDUCED ELASTIN PRODUCTION - Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.08-02-2012
20110059112ANTI-ROBO4 ANTIBODIES AND USES THEREFOR - The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.03-10-2011
20110059111MAMMALIAN RECEPTORS AS TARGETS FOR ANTIBODY AND ACTIVE VACCINATION THERAPY AGAINST MOLD INFECTIONS - The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.03-10-2011
20110059110ANTIBODY (11C7) ANTI NOGO-A AND ITS PHARMACEUTICAL USE - This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.03-10-2011
20110059109Methods for inducing or enhancing an immune response by administering GITR-binding antibodies - The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.03-10-2011
20100255007THERAPEUTIC AGENTS FOR GRAFT-VERSUS-HOST DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT - The present invention provides a novel therapeutic agent for graft-versus-host disease (GVHD).10-07-2010
20130216554Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin - Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.08-22-2013
20130216555METHOD OF PROVIDING DISEASE-SPECIFIC BINDING MOLECULES AND TARGETS - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.08-22-2013
20120128696METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition.05-24-2012
20100255008ANTIBODIES AGAINST HUMAN TWEAK AND USES THEREOF - An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24.10-07-2010
20100322948Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same - The present invention relates to the identification and use of bone morphogenetic protein (BMP)-binding domains of members of the repulsive guidance molecule (RGM) protein family, and polypeptide fragments and fusion proteins derived therefrom. The domains, i.e., peptide fragments and fusion proteins, according to the invention are suitable as agents for the active or passive immunization of individuals, or as diagnostic and therapeutic agents for use for diseases or medical conditions in whose origin or progression a member of the RGM family and a cellular receptor associated with this molecule, such as neogenin and/or BMP in particular, is involved. The invention further relates to monoclonal and polyclonal antibodies directed against the binding domains according to the invention, and against the polypeptides derived therefrom, and to methods for producing the polypeptides, fusion proteins, and antibodies according to the invention.12-23-2010
20100166775S100A9 INTERACTION SCREENING METHOD - A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising: -determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or -determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.07-01-2010
20120141504METHODS FOR TREATING INFLAMMATION USING B7-H4 POLYPEPTIDES AND FRAGMENTS THEREOF - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.06-07-2012
20090041785USE OF ANTI-INTEGRIN ANTIBODIES FOR REDUCING SCAR TISSUE FORMATION - The present invention provides methods that enable the user to identify inhibitors of tissue granulation in and around a wound site, thereby limiting excessive scar formation as the wounded tissue heals. The some granulation inhibitors identified using the methods of the invention inhibit granulation in and around a wound site up to five fold, with a corresponding decrease in the formation of scar tissue when tested on retinal injuries. Granulation inhibitors that can be identified using the methods of the present invention include antibodies, peptides, nucleic acids (aptamers), and non-peptide small molecules.02-12-2009
20120195912Cripto Blocking Antibodies and Uses Thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.08-02-2012
20090074794Anti-TNF Antibodies, Compositions, Methods and Uses - The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.03-19-2009
20090074795Methods for addressing ocular diseases through interference with the wnt signaling pathway - Choroidal neovascularization (CNV) in age-related macular degeneration (AMD) is a leading cause of blindness. Very low-density lipoprotein receptor gene knockout (Vldlr03-19-2009
20090074793High Affinity Human Antibodies to Human IL-4 Receptor - An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (K03-19-2009
20120034240PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.02-09-2012
20090252748Sp35 Antibodies and Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.10-08-2009
20090252746ERYTHROPOIETIN RECEPTOR BINDING ANTIBODIES - The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.10-08-2009
20090110687COMPOSITIONS AND METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.04-30-2009
20080292643LEUKOCYTE INACTIVATION MODULE - The present invention provides a module for reducing the activity of leukocytes which comprises a carrier and a ligand that is linked to the carrier and is suitable for interacting with a leukocyte receptor. Furthermore, the present invention provides a process for reducing the activity of leukocytes using said module. The advantage of the present invention is that after binding the activated leukocytes in the leukocyte inactivation module (LIM), the damaging effect of the cells is inhibited within minutes.11-27-2008
20090110686Antibodies against CCR5 and uses thereof - An antibody binding to CCR5 characterized in that the heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 1, and has advantageous properties for the treatment of immunosuppressive diseases.04-30-2009
20130129748METHODS FOR IDENTIFYING POLYPEPTIDE TARGETS AND USES THEREOF FOR TREATING IMMUNOLOGICAL DISEASES - The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.05-23-2013
20130129749HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same.05-23-2013
20130129750PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.05-23-2013
20100278842ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphB2 antibodies, immunoconjugates, and compositions comprising and methods of using these antibodies and immunoconjugates.11-04-2010
20100297150DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDE INHIBITORS - A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.11-25-2010
20110123551HVEM/BTLA, HVEM/CD 160 AND HVEM/GD CIS COMPLEXES AND METHODS OF USE - The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., antibodies) that bind to the HVEM cis complexes.05-26-2011
20110123550USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS - A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.05-26-2011
20100303832GENES AND POLYMORPHISMS ASSOCIATED WITH AMD - The invention relates to genes, gene polymorphisms, and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of a patient which facilitate assessment of risk for developing such diseases.12-02-2010
20130136753PAXILLIN AS A THERAPEUTIC OR DIAGNOSTIC MARKER FOR CANCER - The present invention relates to methods for assessing the aggressiveness or proliferative activity of a cancer that is capable of both androgen-dependent and steroid-independent growth and proliferation; as well as methods and therapeutic agents for the treatment of such cancers including, among others, prostate cancers, testicular cancers, breast cancers, endometrial cancers, uterine cancers, and ovarian cancers.05-30-2013
20130136754REGULATORY B CELLS AND THEIR USES - The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.05-30-2013
20090214573MODULATION OF BNE DEVELOPMENT - Methods and compositions for modulating bone development are described.08-27-2009
20110008367ANTI-VEGF ANTIBODY - An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target.01-13-2011
20110110957PHENYL-SUBSTITUTED 2-IMINO-3-METHYL PYRROLO PYRIMIDINONE COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain 2-imino-3-methyl pyrrolo pyrimidone compounds, including compounds Formula (II): and include tautomers, steroisomers, or pharmaceutically acceptable salts or solvates of said compounds, stereoisomers, or said tautomers, wherein R05-12-2011
20100255006NOVEL MOLECULES OF THE PYRIN/NBS/LRR PROTEIN FAMILY AND USES THEREOF - Novel PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 proteins, the invention further provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 fusion proteins, antigenic peptides and anti-PYRIN-2, -PYRIN-3, -PYRIN-5, -PYRIN-6, -PYRIN-7, -PYRIN-8, -PYRIN-10, and -PYRIN-11 antibodies. The invention also provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, or PYRIN-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.10-07-2010
20100255005GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.10-07-2010
20110212109Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES - The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.09-01-2011
20090068198Antibody and Uses Thereof - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.03-12-2009
20090068199Methods for Treating and Detecting Beta-Cell Disease - The role of synaptic adhesion molecules in human cell development and function is largely unknown. This invention provides methods to study β-cell function in native tissue through the use of novel adhesion and migrations assays. Through the use of these assays, the inventors have been able to for the first time describe the contribution of SAMs to human β-cell adhesion, spreading, and motility. Furthermore, the inventors have used the results of these assays to develop methods for detection, treatment, and prevention of diseases related to the pancreas.03-12-2009
20110008366INHIBITION OF VERSICAN WITH SIRNA AND OTHER MOLECULES - The present invention provides methods of treating disease or condition in a subject in need thereof, comprising administering the subject a versican inhibitor in an amount effective to treat the disease or condition. Example diseases or conditions include, but are not limited to, fibrotic disease such as fibrotic lung disease, restenosis such as arterial restenosis, atherosclerosis, cancer, and inflammatory disease. Compounds and compositions for carrying out such a method are also described.01-13-2011
20110008368METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER - Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX4OL. OX4OL inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX4OL is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX4OL modulates the generation and function of IL-10 producing Foxp301-13-2011
20110033480METHODS AND COMPOSITIONS INVOLVING NUCLEOTIDE REPEAT DISORDERS - The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting.02-10-2011
20080206262Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) - The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.08-28-2008
20110033481PROSPECTIVE IDENTIFICATION AND CHARACTERIZATION OF BREAST CANCER STEM CELLS - A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary glad of severely immunodeficient mice. These xenograft assays have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.02-10-2011
20100158925Lyophilized formulations of anti-egfr antibodies - In one embodiment, the present invention provides a stable lyophilized formulation comprising an anti-EGFR antibody, preferably cetuximab; lactobionic acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising about 50 mg/mL to about 140 mg/mL of ERBITUX?, about 0.125% lactobionic acid, about 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine.06-24-2010
20110150905HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4 - The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K06-23-2011
20120034241IMMUNOGENIC COMPOSITIONS AND USES THEREOF - The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPI”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the 02-09-2012
20110086045METHOD FOR ENHANCING GROWTH OR INCREASING FEED EFFICIENCY THROUGH REDUCING BINDING BETWEEN ENDOTOXIN AND ITS RECEPTOR IN THE GASTROINTESTINAL TRACT - A method for reducing gastrointestinal inflammation, enhancing growth, or improving feed efficiency in a human or non-human animal is disclosed. The method involves administering to the animal an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4 and CD14 on the cellular surface of a cell in the gastrointestinal tract of the animal. In a preferred embodiment, an antibody against the extracellular domain of TLR4 or CD14 is used to reduce the formation of the complex. A composition that contains the antibody and an ingestible carrier is also disclosed. Further disclosed is a method for producing a peptide for enhancing growth, improving feed efficiency, or both in a human or non-human animal.04-14-2011
20110212108NEUREGULIN/ERBB SIGNALING AND INTEGRIN - The present invention resides in the discovery that the specific interaction between neuregulin 1 (NRG1) and integrin is important for ErbB signaling, which in turn plays an important role in cellular signaling in various physiological processes such as cell proliferation, especially in cancer cells overexpressing ErbB family members. Thus, this invention provides for a novel method for inhibiting ErbB signaling by using an inhibitor of NRG1-integrin binding. A method for identifying inhibitors of NRG1-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting ErbB signaling.09-01-2011
20110243964TREATMENT OF ORTHOPEDIC CONDITIONS - Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorders, diseases, or conditions, and improving recoveries and outcomes of orthopedic procedures or surgeries.10-06-2011
20100255003Immune Disease Medicament Comprising a Modulator of the Binding Between a Heparin Bindin Domain of Thrombospondin-1 and a Beta1 Integrin - An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.10-07-2010
20110212111MHC II Associated Protein and Uses Thereof - The present invention provides a MHC II associated protein, MPYS, and methods for using the same. In particular, the MHC II-associated protein of the present invention mediates apoptosis and influences the susceptibility to infectious diseases. The present invention also provides methods for treating clinical conditions, methods for identifying therapeutically useful compounds using such a protein, and methods for determining susceptibility to infectious disease.09-01-2011
20110212110Compositions and Methods for Detecting TLR3 - The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.09-01-2011
20110250212THERAPY PROCEDURE FOR DRUG DELIVERY FOR TRIGEMINAL PAIN - The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.10-13-2011
20110086042Centrosomal Proteins, Nucleic Acids and Method of Use Thereof - The present invention provides novel isolated centrobin polynucleotides and polypeptides encoded by the centrobin polynucleotides. The invention additionally provides methods of inhibiting cell growth by contacting a cell with a centrobin inhibitor.04-14-2011
20110177095ANTI-HER2 ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2.07-21-2011
20090035320Agents for Regulating Liver Regeneration/Repair - The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI antibodies as active ingredients (particularly, anti-PCI antibodies with the action of neutralizing PCI (anti-PCI neutralizing antibodies)).02-05-2009
20100047256METHODS - The present invention relates to methods of diagnosing, prognosing, preventing or delaying onset of or treating rheumatoid arthritis, methods of distinguishing between different types or stages of rheumatoid arthritis, of identifying an individual at risk of developing rheumatoid arthritis, and of monitoring efficacy of a treatment regime in an individual being treated for rheumatoid arthritis, using a citrullinated enolase peptide to detect or capture antibodies associated with rheumatoid arthritis.02-25-2010
20110086043STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES - The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.04-14-2011
20100136028ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.06-03-2010
20110086044Compositions and Methods to Inhibit HPV Infection - This invention provides compositions and method for inhibiting and treating an HPV infection of LC or tissue containing LC by administering to the LC or tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV infection. It also provides methods to design antiviral and/or anticancer agents for cancers that harbor HPV.04-14-2011
20110081359Alpha 5 beta 1 and its ability to regulate the cell survival pathway - The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin α5β1. Most of the FGF-2-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Using function-blocking antibodies and peptides, a specific contribution of α5β1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated. The present invention thus allows for methods, agents and pharmaceutical compositions that can be used to potentiate the activity of chemotherapy or radiation therapy.04-07-2011
20110081361ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR - The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.04-07-2011
20110076285Methods and Compositions For Treatment of Ocular Fibrosis - Disclosed herein are methods and compositions for treatment of ocular fibrosis, as occurs, for example, during the treatment of glaucoma by trabeculectomy. Compositions comprise modulators of the activity of one or more lysyl oxidase-type enzymes (e.g., LOX, LOXL2), and the methods include methods for making the modulators and methods for administration of the modulators to a subject in need thereof.03-31-2011
20110076284Novel Modulators - Antibodies that modulate insulin receptor signaling are provided.03-31-2011
20120148603PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (I): and tautomers thereof, and solvates, prodrugs, esters, and deuterates of said compounds and said tautomers, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R06-14-2012
20120148602Cancer Treatment With Endothelin Receptor Antagonists - The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.06-14-2012
20110059113GAB2 AMPLIFICATION IN MELANOMA - Provided herein are methods of detecting or inhibiting melanoma growth based on Gab2 protein expression. Gab2 protein was found to be either amplified and/or overexpressed in melanoma. Gab2 protein expression correlated with clinical melanoma progression and higher levels of expression were seen in metastatic melanomas compared to primary melanoma and melanocytic nevi. Over-expression of Gab2 potentiates, whereas silencing of Gab2 reduces, migration and invasion of melanoma cells. Gab2 mediated hyperactivation of Akt signaling in the absence of growth factors and inhibition of the PI3K-Akt pathway decreased Gab2-mediated tumor cell migration and invasive potential. Gab2 over-expression resulted in enhanced tumor growth and metastatic potential in vivo. These results demonstrate a previously undefined role for Gab2 in melanoma tumor progression and metastasis.03-10-2011
20110008369PD-1 BINDING PROTEINS - The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.01-13-2011
20100310578USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET - Methods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.12-09-2010
20100297146IMMUNE SYSTEM PROGRAMMING THROUGH B7-DC - Materials and methods related to modulating immune responses (e.g., altering the polarity of immune responses) are provided.11-25-2010
20100111971ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.05-06-2010
20110250211VARIABLE DOMAINS OF CAMELID HEAVY-CHAIN ANTIBODIES DIRECTED AGAINST GLIAL FIBRILLARY ACIDIC PROTEINS - The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.10-13-2011
20120201835ANTIBODIES SPECIFIC FOR DKK-1 - Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.08-09-2012
20090022737ALDOS AS MODIFIERS OF THE IGF PATHWAY AND METHODS OF USE - Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.01-22-2009
20090317406Phosphorylation of tau by abl - Methods of diagnosing a tauopathy and predicting whether a subject will develop a tauopathy are provided. Also provided are antibody preparations that specifically bind to tau phosphorylated at tyr394 and/or tyr310. Methods of inhibiting tau phosphorylation in a cell and methods of treating a subject having a tauopathy are additionally provided. Methods of treating a subject at risk for a tauopathy are also provided. Additionally, non-human mammals comprising a transgene encoding an abl tyrosine kinase are provided. Also provided are methods of evaluating whether a compound inhibits development of a tauopathy.12-24-2009
20120201836METHODS AND COMPOSITIONS FOR MODULATING T CELL AND/OR B CELL ACTIVATION - The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.08-09-2012
20090214571COLON CANCER RELATED GENE TOM34 - Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon cancer, methods of treating colon cancer and method for vaccinating a subject against colon cancer.08-27-2009
20110212107Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof - Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism comprising determining a change in the level, amount or activity of a fragment of an HFE2A obtained in a sample from said animal relative to the level, amount or activity of a fragment of an HFE2A obtained in a control sample from an unaffected animal, wherein a change identifies said individual as being affect by or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.09-01-2011
20080292642Crystalline anti-human IL-12 antibodies - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.11-27-2008
20080299133Anti-Il-12 Antibody Based Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.12-04-2008
20110256152Methods Of Treating And Preventing Glucose Toxicity - The present invention relates to a method for treating and/or preventing a disease associated with glucose toxicity in a subject which may comprise administering to the subject a compound that reduces the level of Bim, PUMA and/or Bax activity in a cell of the subject. Furthermore, provided is a method for culturing cells susceptible to exposure to high concentrations of glucose, which may comprise delivering to the cells, or progenitor cells thereof, a compound that reduces the level of Bim, PUMA and/or Bax activity in the cells.10-20-2011
20080220000Methods for Generating Improved Immune Reponse - This application relates to a method for generating an improved immune response in a host. The method involves the step of administering a vectored vaccine in the presence of an agent that impairs Treg cell function.09-11-2008
20080254043Drug For Treating Ischemic Disease - The present invention relates to a pharmaceutical composition which includes a tissue factor inhibitor, which is administered after the onset of a thromboembolic ischemic disease, particularly after thrombus or embolus formation; a secondary thrombus formation inhibitor which includes a tissue factor inhibitor, which is administered after primary thrombus formation; a blood flow reduction inhibitor which includes a tissue factor inhibitor to be administered after thrombus formation or embolism formation; and a method of suppressing secondary thrombus formation by inhibiting tissue factor function following formation of a primary thrombus.10-16-2008
20080254042Novel Use of Prrp and Receptor Thereof - The present invention relates to provision of a method of screening a medicament using a disease-associated gene product, an antibody to the disease-associated gene product, and an antisense DNA which suppresses expression of the disease-associated gene product. Specifically, the present invention provides a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, its partial peptide, or a salt thereof.10-16-2008
20110165177Methods of Modulating Immunity - The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.07-07-2011
20110165174Alternatively Transcribed Genes Associated with Memory Consolidation - Methods of identifying gene targets associated with learning and memory and with memory consolidation, as well as to specific nucleic acid molecules that have been discovered to be associated with memory consolidation are provided. Accordingly, the invention also relates to methods of modulating learning and memory function, methods of diagnosing learning and memory disorders, and methods of identifying compounds that modulate learning and memory function via manipulations of the nucleic acid molecules and their products.07-07-2011
20110165175ANTIBODY OF HUMAN ORIGIN FOR INHIBITING THROMBOCYTES AGGREGATION - The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.07-07-2011
20110165176ALDOSTERONE INDUCED VASCULAR ELASTIN PRODUCTION - Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.07-07-2011
20080199480Methods for Identifying Risk of Type II Diabetes and Treatments Thereof - Provided herein are methods for identifying a risk of type II diabetes in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating type II diabetes, and therapeutic and preventative methods applicable to type II diabetes. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.08-21-2008
20110020367Methods of Evaluating Transplant Rejection - The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.01-27-2011
20110033482HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA - Disclosed are inhibitors of HER3 for the treatment of melanoma, in particular melanoma metastases and/or refractory melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis of melanoma.02-10-2011
20100285030Antibodies to Ox-2/Cd200 and Uses Thereof - This application provides methods and compositions for modulating and/or depleting CD200 positive cells.11-11-2010
20100285036Anti-CD100 Neutralizing Antibodies and Methods of Using the Same - Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.11-11-2010
20100285029Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies - The present invention relates to novel compositions and preparations that are effective antifungal agents, and a novel antibody which can be incorporated into the compositions and preparations.11-11-2010
20110135665METHODS FOR TREATING REPERFUSION INJURIES - The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin.06-09-2011
20110135660PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.06-09-2011
20110135664MONOCLONAL ANTIBODIES AGAINST THE RGM A PROTEIN FOR USE IN THE TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION - The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.06-09-2011
20110135662FUNCTION MODIFYING NAv 1.7 ANTIBODIES06-09-2011
20110262460BLOOD-BRAIN BARRIER TARGETING ANTIBODIES - This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention also provides methods of identifying endothelial cell specific antibodies by panning the library against cultured cell monolayers. The invention further allows for identifying endothelial cell receptors that bind the antibody thereby providing target receptors against which to isolate further cognate ligands and their associated transport systems and by which to identify transcytosis transporters targeted by the antibodies.10-27-2011
20110262459Neamine Compositions and Methods of Use Thereof - Provided herein are compositions containing neamine, or a composition containing an agent that possesses one or more activities of neamine, and the research, diagnostic and therapeutic uses of such compounds, such as for the treatment of cancer.10-27-2011
20110052605ASSAY FOR SOLUBLE CD200 - The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.03-03-2011
20110052604Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors - Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.03-03-2011
20110052603 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of modulating tumor necrosis factor-mediated apoptosis and to agents useful for same. More particularly, the present invention contemplates a method of modulating tumor necrosis factor-mediated hepatocyte apoptosis by modulating an intracellular Bim and/or Bid-dependent signalling mechanism. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by aberrant, unwanted or otherwise inappropriate tumor necrosis factor-mediated apoptosis. The present invention is further directed to methods for identifying and/or designing agents capable of modulating the subject Bim and/or Bid-dependent signalling mechanism.03-03-2011
20110052602Diagnosis and Treatment of Age Related Macular Degeneration - Methods, compositions and kits for diagnosis and treatment of age related macular degeneration.03-03-2011
20100330103Antibodies Directed to Alpha V Beta 6 And Uses Thereof - Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.12-30-2010
20100330102IMMUNOGLOBULIN PREPARATION FOR THE TREATMENT OF HIV-1 INFECTION - An immunoglobulin (Ig) preparation containing polyclonal IgG-reactive antibodies (Abs), methods for preparing said preparation and pharmaceutical compositions containing it in admixture with suitable excipients, the use of said preparation or composition, alone or in combination with antiretroviral drugs, for the prophylaxis or treatment of HIV-1 infection.12-30-2010
20110165173THERAPEUTIC AGENT AND DETECTION REAGENT FOR ARTERIOSCLEROTIC DISEASE WHICH TARGETS FOR SALUSIN - The present invention provides a prophylactic and therapeutic agent for arteriosclerotic diseases and a method or reagent for detecting arteriosclerotic diseases. Further, the present invention provides a therapeutic agent for an arteriosclerotic disease, comprising salusin-α as an active ingredient, a therapeutic agent for an arteriosclerotic disease, comprising an antagonist of salusin-β as an active ingredient, and a method for detecting an arteriosclerotic disease, comprising assaying salusin-α in a biological sample.07-07-2011
20110097342BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.04-28-2011
20110177096USE OF GPR151 MODULATORS FOR THE TREATMENT OF PAIN - The present invention relates to nucleic acid arrays used to detect genes which are up or down regulated following a pain stimulus in a mammal. It further relates to the use of GPR151 in methods to detect pain or evaluate the effect of a compound on the level of pain in a mammal. Other aspects of the invention concern a method for screening pharmaceuticals, methods for the treatment of pain and a pharmaceutical composition comprising a GPR151 modulator for the treatment of pain.07-21-2011
20110177097METHODS FOR MODULATING EXPRESSION OF CREB - Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of CREB. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a CREB-specific inhibitor.07-21-2011
20100196400GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.08-05-2010
20090202565TORC POLYNUCLEOTIDES AND POLYPEPTIDES AND METHOD OF USE - The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a TORC related process in a cell as well as a method of inhibiting a TORC-related process in a cell, and a method of inhibiting TORC-related processes in a cell. The invention additionally discloses therapeutic methods of substantially inhibiting the development of, treating, or ameliorating a disease or pathological condition in a subject related to an abnormal level of a TORC-activated process in a cell that includes administering one or more therapeutically effective doses to the subject of either a substance that modulates accumulation of a TORC polypeptide in a subcellular region of the cell, or of a substance that inhibits expression of a TORC polypeptide in the cell. In an additional aspect a method of identifying an agent that modulates the activity of a TORC-related process in a cell is disclosed. In still a further aspect the invention relates to a method of detecting the presence or quantifying the amount of a TORC polypeptide in a sample. In a further aspect, a method is disclosed of determining whether the amount of a TORC polypeptide in a sample differs from the amount of the TORC polypeptide in a reference. An additional aspect relates to a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a first subject, wherein the subcellular localization of a TORC polypeptide in the pathology is known to differ from the subcellular localization of the TORC polypeptide in a nonpathological state.08-13-2009
20090202564METHODS OF ISOLATING STEM CELLS - The present inventors discovered for the first time that labeling cell nuclei makes it possible to efficiently isolate stem cells. Namely, it was elucidated that stem cells with labeled nuclei remained labeled even after cell division, and showed self-renewing and long-living abilities characteristic of stem cells. Efficient isolation of stem cells is possible, for instance, by labeling the nuclear of each cell in a heterogeneous cellular group followed by selecting those cells that maintain a labeled state even after cell division. The present invention provides methods for enabling visualization of stem cells of animal tissues in a living state by labeling using the essential functions of the stem cells, and methods for simply and easily isolating the stem cells in a fresh state without using at all genetic manipulation or artificial markers.08-13-2009
20090202563C20ORF23 as modifier of the IGFR pathway and methods of use - Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.08-13-2009
20110189201MODULATION OF BONE DEVELOPMENT - Methods and compositions for modulating bone development are described.08-04-2011
20110189199METHODS FOR P2RY5 MEDIATED REGULATION OF HAIR GROWTH AND MUTANTS THEREOF - The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention further provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject.08-04-2011
20110189198Compositions and Methods for Diagnosing and Treating an Inflammation - An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.08-04-2011
20110135663ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The subject invention provides antibodies, or binding fragments thereof, that specifically bind to human IGF-IR. Also provided are nucleic acid molecules encoding the antibodies and binding fragments of the subject invention and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.06-09-2011
20110262458Alzheimer's Disease Treatment Method - The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Ab40 and Ab42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.10-27-2011
20100028363METHODS FOR TREATING PSORIASIS - The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.02-04-2010
20100028362MODULATION OF T HELPER CELL-MEDIATED IMMUNE RESPONSES - Provided herein are methods for modulating one or more of a T-helper cell or monocyte lineage cell-mediated immune response in a subject, the method comprises administering to the subject an effective amount of a compound which binds to surface membrane immunoglobulin D (smIgD). Also provided are methods of diagnosis of one or more of a T-helper cell or monocyte lineage cell-mediated immune disease, and compositions and kits for use in such methods.02-04-2010
20120308581COMPOSITIONS AND METHODS FOR DETECTING TLR3 - The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.12-06-2012
20090136519Tissue Protective Cytokine Receptor Complex, Assays for Identifying Tissue Protective Compounds and Uses Thereof - The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one βc Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.05-28-2009
20090004204Assays and methods using biomarkers - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR01-01-2009
20080260753Mouse Models of Crohn's Disease and a Method to Develop Specific Therapeutics - Provided are compositions, transgenic animals and methods for screening and analyzing agents useful for treating inflammatory bowel diseases. Also provided are methods to treat inflammatory bowel disease, Crohn's disease and Blau syndrome.10-23-2008
20100221263Anti-Sclerostin Antibodies - Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.09-02-2010
20100166774Stable Protein Formulations - The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.07-01-2010
20100285033COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF - Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.11-11-2010
20110117111MICRORNA-BASED DIAGNOSTIC TESTING AND THERAPIES FOR INFLAMMATORY BOWEL DISEASE AND RELATED DISEASES - The present invention is based, at least in part, on the novel discovery that certain microRNAs are associated with inflammatory bowel diseases and other related diseases. Accordingly, the invention relates to microRNA-based compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating inflammatory bowel diseases and other related diseases.05-19-2011
20110117112SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT - The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.05-19-2011
20110117110ANTI-EGFR ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR.05-19-2011
20100221260IMMUNOGLOBULINS - The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.09-02-2010
20110081360Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.04-07-2011
20100255004RECEPTOR TYROSINE KINASE PROFILING - The invention provides novel methods for designing and administering therapeutic treatments for subjects afflicted with cancer. One aspect provides methods of identifying RTK pathways in a cancer and formulating treatment plans based on a plurality of RTK inhibitors. The invention further provides methods for evaluating candidate tyrosine kinase inhibitors for therapeutic efficacy.10-07-2010
20110305711CGRP ANTIBODIES - The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.12-15-2011
20110305710NOVEL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION - This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin, insulin like growth factor, their isoforms, their analoges, their gene-engineered modifications. Furthermore, the formentioned compositions and combinations are provided for coadministration with antiglaucoma agents, currently in clinical use, for the treatment or prophylaxis of glaucoma and ocular hypertension, for lowering of intraocular pressure, for increasing success rate of surgical procedures for the treatment or prophylaxis of glaucoma, and for preserving retinal ganglion cells.12-15-2011
20110305709CALCIUM SENSOR STIM1 AND THE PLATELET SOC CHANNEL ORAI1 (CRACM1) ARE ESSENTIAL FOR PATHOLOGICAL THROMBUS FORMATION - The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai12-15-2011
20100028364INHIBITION OF SOX9 FUNCTION IN THE TREATMENT OF PROTEOGLYCAN-ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS - A method of treating a pathophysiological condition caused by the production of growth-inhibiting proteoglycans is provided. It is based on the finding that down-regulation of SOX9 results in decreased production of growth-inhibiting factors such as proteoglycans, and increased production of growth-promoting factors such as a laminin and fibronectin. The method of the present invention comprises the inhibition of SOX9 expression and function with an inhibitor such as an antisense oligonucleotide or a siRNA.02-04-2010
20110070244METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA - Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.03-24-2011
20110070243COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.03-24-2011
20080206261METHODS FOR SCREENING, TREATING AND DIAGNOSING INFLAMMATORY BOWEL DISEASE AND COMPOSITIONS THEREOF - Methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of IBD. In particular, the present invention is directed to the identification of novel targets that are IBD differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit IBD. Methods for determining the long-term prognosis in a subject are also provided.08-28-2008
20120039912RSPONDIN-3 INHIBITION IN BONE DISORDERS - The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption.02-16-2012
20120039911CD93 OR USE OF SOLUBLE FRAGMENT THEREOF - The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.02-16-2012
20130011417COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES - The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said derivatives. The colchicine derivatives according to the present invention exhibit superior immunomodulatory effects as compared with conventional immunomodulators or colchicines, and therefore can be valuably used as an immunomodulator for modulating an acute or chronic immune response in organ transplantation.01-10-2013
20100226930Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.09-09-2010
20120148604TRP INHIBITORS AND USES THEREOF - The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.06-14-2012
20080220001CA IX-Specific Inhibitors - Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Still further, the CA IX-specific inhibitors can be used therapeutically to selectively target hypoxic cells expressing activated CA IX. The CA IX-specific inhibitors can be labelled or conjugated to radioisotopes for radiotherapy of hypoxic cells. Alternatively, the CA IX-specific inhibitors can be used for gene therapy coupled to vectors for targeted delivery to hypoxic preneoplastic/neoplastic cells expressing activated CA IX on their surfaces.09-11-2008
20100285032ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) IN BONE AND CARTILAGE FORMATION AND METHODS AND COMPOSITIONS RELATING TO SAME - ERRγ is expressed in bone and cartilage in vivo and osteoblastic and chondrocytic cells in vitro. ERRγ is a transcriptional activator of an osteoblast-associated osteopontin (OPN) and chondrocyte-associated (Sox9) gene in osteoblasts and chondrocytes respectively. Knockdown of ERRγ expression by antisense oligonucleotide strategies in osteoblastic cell cultures reduces alkaline phosphatase activity. Together these findings indicate that ERRγ is expressed in and plays a functional role in bone and cartilage. The results also indicate that agonists and antagonists of ERRγ may be useful as therapeutic agents in a wide variety of diseases affecting bones and joints.11-11-2010
20090191219METHODS FOR DIAGNOSING AND TREATING OBESITY BY MODULATING THE ACTIVITY OF AUTO-ANTIBODIES AGAINST THE MELANOCORTIN-4 RECEPTOR - Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor, in particular which prevent the binding of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor.07-30-2009
20110064746TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS - The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.03-17-2011
20110171238NOVEL STRA6 POLYPEPTIDES - The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.07-14-2011
20110318366BIOLOGIC COMPOUNDS - The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.12-29-2011
20120301487METHOD FOR IN-VIVO BINDING OF CHROMATIN FRAGMENTS - A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.11-29-2012
20120301485Juvenile Hemochromatosis Gene (HFE2A) Cleavage Products and Uses Thereof - Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.11-29-2012
20120301484REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T11-29-2012
20120301483COMPLEMENT PATHWAY INHIBITORS BINDING TO C5 AND C5A WITHOUT PREVENTING THE FORMATION OF C - The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.11-29-2012
20120301482METHODS AND COMPOSITIONS FOR TREATMENT OF LUNG INJURY - The present invention provides a method to treat a condition related to injury of lung epithelial cells in a subject by administering a compound that binds FgfR2b, for example to promote proliferation of lung epithelial stem cells, as well as such compounds in pharmaceutical formulations. The invention also provides for methods to treat a condition related to injury of lung epithelial cells by isolating cells expressing FgfR2b, multiplying the cells and introducing the multiplied cells for repair of lung injury. Related methods for detecting lung injury by detecting the level of expression of FgfR2b well as for treating a condition related to proliferation of lung epithelial cells by administering a compound that binds to FgfR2b, to block receptor signaling are also provided.11-29-2012
20110318367NOVEL TARGETS FOR TREATMENT OF HYPERCHOLESTEROLEMIA - In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided.12-29-2011
20110318368ANTI-HUMAN ALPHA9 INTEGRIN ANTIBODY AND USE THEREOF - The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.12-29-2011
20110318365METHODS FOR TREATMENT OF DEGENERATIVE DISEASE ASSOCIATED WITH APOPTOSIS - A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce or eliminate the degenerative disease in the mammalian subject without having any substantial angiogenic effect across all dosage levels.12-29-2011
20120207768CD38 AND OBESITY - This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided.08-16-2012
20120045459Methods for Treating Autophagy-Related Disorders - Methods for treating autophagy-related disorders with agents which modulate expression of the gene encoding tyrosine phosphatase receptor type sigma (PTPRS) or which modulate the biological activity of the PTPRS gene product (PTPsigma). Methods for modulating autophagy in a cell with agents which modulate expression of PTPRS or which modulate the biological activity of PTPsigma; and related diagnostic methods, screening methods, and agents.02-23-2012
20120003246Novel composition and methods for the treatment of psoriasis - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis.01-05-2012
20120003242MODULATING PDX-1 WITH PCIF1, METHODS AND USES THEREOF - This invention relates to PCIF1 and its use as a target for the improvement of pancreatic islet β cell mass and function in diabetes. Specifically, the invention relates to the use of compounds capable of modulating the expression or function of PCIF1 and their effect on the function of Pdx-1.01-05-2012
20120003245ANTI-COBRA TOXIN ANTIBODY FRAGMENTS AND METHOD OF PRODUCING A VHH LIBRARY - A method of constructing a V01-05-2012
20120003243YEAST ECTOPICALLY EXPRESSING ABNORMALLY PROCESSED PROTEINS AND USES THEREFOR - Disclosed are yeast ectopically expressing abnormally processed proteins and methods of screening to identify compounds that modulate the function of such abnormally processed proteins in yeast. Compounds identified by such screens can be used to treat or prevent diseases associated with abnormally processed proteins or protein misfolding. Such diseases include Parkinson's Disease, Parkinson's Disease with accompanying dementia, Lewy body dementia, Alzheimer's disease with Parkinsonism, and multiple system atrophy.01-05-2012
20120009203Depletion of cancer stem cells - Compositions and methods are provided for killing of cancer stem cells, and for the transplantation of pluripotent stem cells and differentiated cells derived therefrom.01-12-2012
20100183628RANDOM HOMOZYGOUS GENE PERTURBATION (RHGP) WITH THERMAL ASSYMETRIC INTERLACED (TAIL)-PCR - A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail.07-22-2010
20110076283METHOD FOR PREDICTING AND DIAGNOSING BRAIN TUMOR - The present invention relates to a method for predicting or diagnosing outcome of concomitant chemo-radiotherapy of a subject suffering from brain tumor. The present invention further relates to compositions and methods for treatment or prevention of tumor resistance in a subject suffering from a brain tumor and to a kit useful for predicting or diagnosing the tumor resistance in a subject treated with concomitant chemo-radiotherapy.03-31-2011
20100062000Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations - CD44 is an integral hyaluronan receptor that can either promote or inhibit motogenic signaling in tumor cells. Rhamm is a non-integral cell surface (CD168) and intracellular hyaluronan binding protein that promotes cell motility in vitro and whose expression is strongly upregulated in aggressive tumors. The present invention describes compositions and methods for the prognosis and diagnosis of cancer by the detection of CD44/Rhamm complexes. The use of labeled Rhamm-binding agents in culture and in vivo to identify tumorigenic progenitor cells that exhibit an aggressive phenotype characterized by high Rhamm and CD44 expression is further described. Specific methods include using hyaluronan to target imaging or therapeutic agents to these progenitor tumor subsets in breast and likely other cancers.03-11-2010
20120058126ANTI-VEGFR-3 ANTIBODY COMPOSITIONS - The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease.03-08-2012
20120058127PAR2 Agonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections - The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing influenza virus type A infections. More particularly, the invention relates to a PAR2 agonist for use in the treatment or prevention of an influenza virus type A infection.03-08-2012
20120058125METHODS RELATING TO PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES - This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides.03-08-2012
20090068201METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA - The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.03-12-2009
20100239596GRP78 AND TUMOR ANGIOGENESIS - Methods of preventing or reducing tumor angiogenesis in a subject, comprising administering to the subject one or more agents that inhibit expression or activity of GRP78 are provided. Also provided are methods of sensitizing tumor blood vessels to a chemotherapeutic agent comprising administering to the subject one or more agents that inhibit expression or activity of GRP78. Provided is also a method of reducing tumor microvessel density in a subject, comprising selecting a subject with a tumor, wherein the subject is in need of reduction of tumor microvessel density, and administering to the subject one or more agents that inhibit expression or activity of GRP78.09-23-2010
20080286286Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor - OX40L inhibits the generation of IL-10-producing Tr1 cells from naïve and memory CD4+ T cells induced by the immunuosuppressive drugs dexamethasone and vitamin D3. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. OX40L also strongly inhibits the generation of IL-10-producing Tr1 cells induced by two physiological stimuli provided by inducible costimulatory ligand and immature DCs and inhibits the production of IL-10 by regulatory T cells. It has thus been shown that signaling the OX40-receptor on human T cells by monoclonal antibodies, small molecules, or OX40L regulates the generation and function of IL-10 producing immunosuppressive T cells. Also provided are high throughput methods for identifying substances that promote or inhibit the generation and function of IL-10 producing T cells. Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L.11-20-2008
20120114669COMPOSITIONS AND METHOD FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-β (Aβ) to FcγRIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an FcγRIIb protein or a variant thereof, an FcγRIIb extracellular domain, an anti-FcγRIIb antibody, an FcγRIIb-specific peptide and an FcγRIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of Aβ and the neurotoxicity, neuronal cell death and memory impairment mediated by Aβ by inhibiting the binding between Aβ and FcγRIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.05-10-2012
20120114667TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF - The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.05-10-2012
20120114666NEUROLOGICAL AUTOIMMUNE DISORDERS - The invention relates to a method of diagnosing an autoimmune neurological disorder in a mammal comprising the step of detecting, in a bodily fluid sample from the mammal, autoantibodies to an epitope of at least one Kv1-complex protein; and related methods, assay kits, isolated or purified autoantibody or antibody fragments, or uses thereof.05-10-2012
20100196401USE OF RAPAMYCIN TO INHIBIT IMMUNE RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS - Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene.08-05-2010
20120058128ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.03-08-2012
20120064093ANTIBODY - The invention relates to antibodies to 03-15-2012
20120156222PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to a purified antibody that specifically binds an α-synuclein protofibril.06-21-2012
20090220527AFFINITY OPTIMIZED EPHA2 AGONISTIC ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.09-03-2009
20120207769Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).08-16-2012
20120207767Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).08-16-2012
20120177665METHOD OF DIAGNOSING AND TREATING INTERSTITIAL CYSTITIS - A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and/or inhibiting its binding to its ET07-12-2012
20120177664Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.07-12-2012
20100285031Hox Compositions and Methods - The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders in a subject.11-11-2010
20090297537Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level - The present invention concerns combination of an amount of a BRS-3 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the BRS-3 agonist alone and by the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing obesity and diabetes and conditions related thereto and conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.12-03-2009
20100203065HUMAN LIVER REGENERATION ASSOCIATED PROTEIN AND THE USE THEREOF - This invention provides a novel human liver regeneration associated protein hLRTM4 and the polynucleotide which encodes the hLRTM4 protein. Furthermore, this invention provides a method of preparing and using hLRTM4 protein, and its polynucleotides. hLRTM4 protein can be used to treat liver injury, and its antagonists (e.g. antisense nucleic acids and antibodies) can be used to treat hepatocellular carcinoma. This invention also provides the corresponding pharmaceutical compositions.08-12-2010
20100203064METHODS AND COMPOSITIONS FOR MODULATING WOUND REPAIR - The present invention relates to a method of modulating repair of a wound. The method includes modulating expression and/or activity of Flightless I in cells involved in repair of the wound.08-12-2010
20120156223Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens - Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided.06-21-2012
20120156220METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.06-21-2012
20090297538NEUROTOXIC OLIGOMERS - This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.12-03-2009
20120114668METHOD FOR MODULATING ANGIOGENESIS USING FIBROMODULIN - Described herein are compositions and uses thereof to inhibit or enhance the activity of fibromodulin (FMOD). Such compositions are useful in methods for treatment of age-related macular degeneration involving choroid neovascularization in a subject comprising administering a therapeutically effective amount of a fibromodulin activity inhibitor to the subject.05-10-2012
20100098712Pharmaceutical formulation of an antibody against OX40L - Pharmaceutical formulations of an antibody against OX40L and processes for making the same.04-22-2010
20120156221Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders - The invention relates to compounds which activate the BASIGIN signaling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.06-21-2012
20110104182CD40 ANTIBODY FORMULATION AND METHODS - The present invention provides a method of treating tumor in a patient comprising administering to said patient a CD40 agonist antibody according to an intermittent dosing schedule. The present invention also provides a method of treating tumor in a patient comprising administering a combination of a CD40 agonist antibody and a DNA replication inhibitor. Also provided is a formulation for use in the treatment.05-05-2011
20110104181MODULATION OF SYNAPTOGENESIS - The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or an α2δ subunit of a calcium channel.05-05-2011
20120251553BIOMARKERS FOR SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS - The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder.10-04-2012
20100092489COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS - The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.04-15-2010
20120121609FIBROBLAST GROWTH FACTOR RECEPTOR-1 INHIBITORS AND METHODS OF TREATMENT THEREOF - The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (EGFR)-1(IIIb), EGFR-1(IIIc), and/or EGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing EGFR-1 or EGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.05-17-2012
20120121610THERAPEUTIC AGENT AND ASSAY - The present invention relates to an agent that is useful in the treatment of a cell proliferative disease or disorder, and an assay for identifying such an agent.05-17-2012
20120121608USE OF SAM68 FOR MODULATING SIGNALING THROUGH THE TNF RECEPTOR - Sam68 plays a role in TNF-dependent signaling, including NF-kB signaling and extrinsic activation of apoptosis. In some embodiments, inhibitors of Sam68 are administered to inhibit TNF-dependent signaling, for example to inhibit NF-kB signaling or apoptosis in a patient in need. In some embodiments, functional Sam68 is administered to increase TNF-dependent signaling, for example to induce apoptosis in a patient in need. In some embodiments, methods are provided determining whether the TNF-dependent or TNF-independent branch of a signaling pathway is active in a cell or cells, or for drug screening applications.05-17-2012
20100247552PAK MODULATORS - The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering p21-activated kinase (PAK) modulators to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides PAK modulators and pharmaceutical compositions comprising PAK modulators. The present invention further provides methods for identifying and/or characterizing PAK modulators.09-30-2010
20100247553Goodpasture Antigen Binding Protein - The present invention provides isolated nucleic acid sequences and expression vectors encoding the Goodpasture antigen binding protein (GPBP), substantially purified GPBP, antibodies against GPBP, and methods for detecting GPBP.09-30-2010
20100247554USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS - This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject.09-30-2010
20100247551Use of Lipocalin 2 in the Regulation of Insulin Sensitivity - Methods of identifying compounds that modulate lipocalin 2 activity or expression are described, as are methods of reducing insulin resistance or increasing insulin sensitivity by administering compounds that modulate lipocalin 2 expression. Methods of diagnosing insulin resistance or related conditions, by measuring lipocalin 2 activity, are also described.09-30-2010
20120164159Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof - A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.06-28-2012
20120164157METHOD OF TREATING STROKE WITH THROMBOLYTIC AGENT - A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus. Also described are kits for carrying out this method.06-28-2012
20120128698DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES - The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist.05-24-2012
20120128697NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples.05-24-2012
20120128694THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer.05-24-2012
20120128693CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF - Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.05-24-2012
20120164158Anti-ADDL Monoclonal Antibody and Use Thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.06-28-2012
20120128695TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF - The invention provides a novel family of biologically active neuropeptides and the nucleic aid molecules coding for same. The peptides are derived for the C-terminus of the teneurin family peptides (Ten M1-4). These novel peptides, referred to as teneurin C-terminal associated peptides (TCAPs) are active in neuronal communication and are implicated in a number of neuropathologies. They are particularly useful in modulating stress responses and anxiety and in the treatment of cancer.05-24-2012
20100143382MODULATION OF RHAMM (CD168) FOR SELECTIVE ADIPOSE TISSUE DEVELOPMENT - Herein is described the methods and compositions for modulation of Rhamm, also known as CD 186, and its effects on wound repair, muscle differentiation, bone density and adipogeneisis through its ability to regulate mesenchymal stem cell differentiation. Compositions and methods are provided for blocking Rhamm function for selectively increasing subcutaneous, but not, visceral fat. Compositions and methods for modulating Rhamm in wound repair are also described.06-10-2010
20100209436METHOD FOR TREATING DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION - The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered OPA1 processing. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof is administered to a patient in need of medical intervention. The present invention also relates to the use of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof for the preparation of a pharmaceutical composition for the mentioned therapeutic intervention. The present invention further relates to a method of screening for a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof comprising the use of OPA1.08-19-2010
20120213801Phosphorylated Twist1 and cancer - The present application relates to methods for treating cancer in a subject by modulating the phosphorylation of the Serine 42 of Twist1 by administering to said subject a therapeutically effective amount of a modulator of said phosphorylation of the Serine 42 of Twist1. Antibodies, uses methods and biomarkers based on the phosphorylation of the Serine 42 of Twist1 are also provided.08-23-2012
20110182916Use of Agonists of Integrin Alpha 5 for Inducing the Osteogenic Differentiation of Mesenchymal Stem Cells - The invention relates to the use of agonists of integrin alpha for promoting osteoblast differentiation of mesenchymal stem cells. These agonists are useful in particular for enhancing osteogenesis in the treatments of diseases associated with bone loss or insufficient bone formation.07-28-2011
20110182917THERAPEUTIC OR PROPHYLACTIC AGENT FOR GENERALIZED PAIN SYNDROME - Provided is a therapeutic or prophylactic agent for generalized pain syndrome, for which no cause and therapies have been established. A therapeutic or prophylactic agent for generalized pain syndrome containing an LPA1 antagonist or autotaxin-inhibiting substance as an active ingredient. The pharmaceutical is preferably administered to the central nervous system. The generalized pain syndrome is preferably fibromyalgia, chronic fatigue syndrome or hypersensitivity colitis.07-28-2011
20110182915THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR OSTEOARTHRITIS - A method for treatment of disease classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis, the method includes a step of administrating an agent containing an anti-Fas IgM antibody as an active ingredient.07-28-2011
20110182914METHODS AND COMPOSITIONS - The invention relates to methods for modulating granulocyte activation and migration, use of such methods in the treatment of diseases and compositions which may be employed in such methods and uses. In particular, the modulation of granulocyte activation/migration is achieved by increasing or decreasing the amount of lactoferrin in the vicinity of said granulocytes.07-28-2011
20120213802PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections - The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist.08-23-2012
20120213800Methods for treating and diagnosing disease - The present invention provides methods for the diagnosis and/or treatment of chronic kidney disease, immune complex-mediated GN, rheumatoid arthritis, and pulmonary fibrosis, and methods for identifying compounds for such therapeutic use.08-23-2012
20120135008METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.05-31-2012
20120135007Anti-LPS Enriched Immunoglobulin Preparations For The Treatment And/Or Prophylaxis Of A Pathologic Disorder - The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders.05-31-2012
20120219567Methods Relating to Peripheral Administration of Nogo Receptor Polypeptides - This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides.08-30-2012
20120135009Cleaved and Phosphorylated CRMP2 as Blood Marker of Inflammatory Diseases of the Central Nervous System - The present invention relates to a method for in vitro prognosis, diagnosis and/or monitoring of an inflammatory disease of the central nervous system in a subject, said method comprising detecting, in a sample of cells of the immune system from the subject, the presence of a Collapsin Response Mediator Protein 2 (CRMP2) which is phosphorylated on tyrosine 479 (Y479), and optionally further phosphorylated on serine 465 (S465), wherein the detection of the presence of Y479-phosphorylated CRMP2, which is optionally further phosphorylated on serine 465, is indicative of an inflammatory disease of the central nervous system.05-31-2012
20080206263Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration - The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the HTRA08-28-2008
20100172919NOVELTREATMENT FOR NEUROLOGICAL DISORDERS - Provided are novel drugs and methods in the treatment as well as diagnosis of neurological disorders such as Alzheimer's disease and amyloid-beta pathology/amyloidosis. More specifically, the use of erythropoietin and analogs thereof for the treatment of Aβ peptide related brain impairments is described. Furthermore, the use of claudin-5 and variants thereof as biomarker for Alzheimer's disease and for the progression of Alzheimer's disease, respectively, is provided.07-08-2010
20120171224Anti-ADDL Antibodies and Uses Thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.07-05-2012
20120251554ANTI-CD33 ANTIBODIES AND USE THEREOF FOR IMMUNOTARGETING IN TREATING CD33-ASSOCIATED ILLNESSES - The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 1010-04-2012
20120076803ANTIBODIES TO TROPONIN I AND METHODS OF USE THEREOF - The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.03-29-2012
20100047255NOVEL ACTIVATION AND TRANSFER CASCADE FOR UBIQUITIN - A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.02-25-2010
20100272737Novel Peptides and Protein and Uses Thereof - The present invention relates to a novel gene encoding a protein termed voltage gated calcium channels β subunit anchoring regulator protein (VDCC BARP) or a peptide fragments thereof. The present invention also relates to the use of VDCC BARP in Modulation of voltage gated calcium channels via altering the concentration of VDCC BARP or a peptide fragments thereof.10-28-2010
20100008935METHOD FOR IDENTIFYING THERAPEUTICAL TARGETS IN TUMORS, THE USE THEREOF AND MEANS FOR DETERMINING AND TARGETING ANGIOGENESIS AND HEMOSTASIS RELATED TO ANDENOCARCINOMAS OF THE LUNG - Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF/SF) are potent mitogens with proven angiogenic activities in human and animal disease models. These growth factors display little overlap in angiogenesis signaling cascades. The application reports angiogenesis in lung adenocarcinomas to be coordinated by hemostatic events. The invention relates to a method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies, the use of novel targets for identifying, determining, and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung, and the use of the therapeutical targets identified for screening and determining means and/or drugs. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies. Furthermore the aim is the use of novel therapeutical targets identified by the method for screening and determining beneficial means and/or drugs, and means and drugs for identifying, determining and treating angiogenesis and hemostasis related to adenocarcinomas, in particular of advanced stage tumors of the lung. The method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies, comprising the steps of—isolating RNA (1) from the tissue of the tumor; —determining for the isolated RNA (1) a gene expression profile (2) of at least two genes, wherein at least one gene (3) is coding for a VEGF activity modulator and at least one gene (4) is coding for a hemostatic factor by screening the presence of mRNA coding for the factors to be screened and by determining the levels of expression of thereof; —determining the changes of expression of the at least two genes screened by the gene expression profile (2) in comparison with healthy tissue or with an early stage tumor; and—identifying the therapeutical target as a hemostatic factor, being upregulated or down-regulated.01-14-2010
20120315286COMPOSITIONS AND METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.12-13-2012
20100297145Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent - Disclosed is an apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer or the like which comprises a compound capable of inhibit the expression or function of PCA-1 as an active ingredient. Also disclosed is a method for screening of a compound for use in the promotion of apoptosis, the inhibition of cell proliferation or the prevention/treatment of cancer, which comprises selecting a compound capable of inhibit the expression or function of PCA-1, or the like.11-25-2010
20100297149COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.11-25-2010
20120189643Toll Like Receptor 3 Antagonists, Methods and Uses - Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.07-26-2012
20120258122Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 and Uses Thereof - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.10-11-2012
20120258121GENERATION OF ANTI-FN14 MONOCLONAL ANTIBODIES BY EX-VIVO ACCELERATED ANTIBODY EVOLUTION - The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.10-11-2012
20120189642IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (a) and include tautomers, solvates, prodrugs, esters, and deuterates thereof, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R07-26-2012
20120263736METHOD FOR PREDICTING AND TREATING A STERILE INFLAMMATION AND DISCRIMINATING BETWEEN STERILE AND INFECTIVE INFLAMMATION - The invention provides methods for predicting the likelihood that a subject will develop a sterile inflammation or will have an increased propensity to later develop a sterile inflammation, for determining whether a subject with tissue damage should be administered an antimicrobial agent (at full or a reduced dosage) or an anti-inflammatory agent, and for treating a subject with tissue damage. In the methods, an increased ratio of the amount of mitochondrial nucleic acid or peptide to the amount of microbial nucleic acid or peptide indicates a subject that has an increased likelihood of developing a sterile inflammation or an increased propensity to later develop a sterile inflammation, or a subject that should not be administered, or that should be administered at a reduced dosage, an antimicrobial agent or one or more anti-inflammatory agents and not an antimicrobial agent. Kits for detecting mitochondrial and/or microbial nucleic acids or peptides are provided.10-18-2012
20090017044Antibodies to the Human Prolactin Receptor - This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.01-15-2009
20090017045Polynucleotides Encoding Growth Differentiation Factor-8 - A transgenic non-human animal of the species selected from the group consisting of avian, bovine, ovine and porcine having a transgene which results in disrupting the production of and/or activity of growth differentiation factor-8 (GDF-8) chromosomally integrated into the germ cells of the animal is disclosed. Also disclosed are methods for making such animals, and methods of treating animals with antibodies or antisense directed to GDF-8. The animals so treated are characterized by increased muscle tissue.01-15-2009
20110123549Antibodies to EphA3 - The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.05-26-2011
20110123548COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS - The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.05-26-2011
20100310579METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER - The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down-regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis.12-09-2010
20120231018HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I09-13-2012
20120231019FIBROSIS INHIBITOR - An objective of the present invention is to provide methods for treating or preventing fibrotic diseases, which are based on the novel finding that fibrosis is suppressed by administering ER-TR7 to a subject.09-13-2012
20120231016Pharmaceutical Composition for Inhibiting Histone H4 and Manufacturing Method Thereof - The present invention discloses a pharmaceutical composition for inhibiting histone H4 and a manufacturing method thereof. The pharmaceutical composition comprises an anti-histone H4 antibody and a pharmaceutically acceptable excipient. The hair loss resulted from medications, including cancer drugs, can be reduced by using the pharmaceutical composition of the present invention, thereby resolving mental depression and promoting prognosis effects for patients.09-13-2012
20100239597Anti-ADDL monoclonal antibody and use thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.09-23-2010
20080299134Recombinant Anti-Interleukin-9 Antibodies - The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.12-04-2008
20110002945Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins - Subunits of antibodies, such as a light chain or a heavy chain, selectively bind to amyloid fibrils and oligomers.01-06-2011
20120269823VIRULENT ISOLATE OF NEOSPORA CANINUM AND ITS USES - The present invention relates to a new isolate of 10-25-2012
20120328628ANTIBODIES TO CONFORMATIONALLY TRAPPED PROTEINS - The present invention provides methods for generating antibodies to specific conformations of proteins. The conformation specific antibodies of the invention can be put to a variety of uses including diagnosis and treatment of diseases and for screening for compounds that induce conformational changes in proteins upon binding.12-27-2012
20120328630METHODS FOR TREATING AND/OR LIMITING DEVELOPMENT OF DIABETES - The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.12-27-2012
20120328631EP1 INHIBITION - Provided herein are methods of accelerating bone fracture healing in a subject. Also provided herein are methods of treating or preventing osteoporosis in a subject. Further provided are methods of screening for an agent that accelerates bone fracture healing or treats or prevents osteoporosis.12-27-2012
20120328629Therapeutic Applications Targeting SARM1 - The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α/Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression.12-27-2012
20110045002METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.02-24-2011
20110045001Transfection results of non-viral gene delivery systems by influencing of the innate immune system - The innate immune system of eukaryotes is able to recognise foreign genetic material by means of Toll-like receptors and to initiate signal transduction cascades that trigger an antiviral state of cell populations by way of an interferon response. That antiviral state is also a barrier for non-viral gene delivery systems. If the signal transduction cascade is interrupted intracellularly or intercellularly, transfection efficiencies of non-viral gene delivery systems can be increased and undesirable changes in the expression profile can be avoided. Since RNA-interference is to be attributed to the antiviral state, the RNAi machinery is likewise activated after activation of the innate immune system. In that way, knock-down efficiencies on transfection with siRNA can be increased.02-24-2011
20120269826ANTI-CD3 ANTIBODY DOSING IN AUTOIMMUNE DISEASE - Provided herein are methods of administering anti-CD3 antibodies or antigen-binding fragments thereof to an animal. In certain embodiments, the anti-CD3 antibody or fragment thereof does not bind or has reduced binding to at least one class of Fc (gamma) receptors. In certain embodiments, the animal has an immune-related disease.10-25-2012
20120269825METHODS OF MODULATING THE OX40 RECEPTOR TO TREAT CANCER - Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. OX40L inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX40L modulates the generation and function of IL-10 producing Foxp310-25-2012
20120269824THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONAL ANTIBODY - Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.10-25-2012
20120321643ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF - The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×1012-20-2012
20110236401COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided.09-29-2011
20110236400TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS - Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine.09-29-2011
20120321644METHODS FOR DIAGNOSING MOOD DISORDERS - The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Aβ protein, including Aβ12-20-2012
20120282277Method for Treating Arteriosclerosis - The invention relates to a method for identifying substances with antiapoptotic activity, where 11-08-2012
20120282275METHODS AND COMPOSITIONS FOR REGULATION OF NEUROLOGICAL CONDITIONS - The invention relates to methods and compositions for regulation of neurological conditions. In particular, methods and compositions for the modulation of the chemokine receptor 1 (CX3CR1) and its ligands are described.11-08-2012
20120282276BIOMARKERS PREDICTIVE OF PROGRESSION OF FIBROSIS - The present invention provides methods and kits for prognosing the progression of fibrosis in a subject having fibrosis, as well as methods for identifying a compound that can slow down the progression of fibrosis in a subject having fibrosis, methods of monitoring the effectiveness of a therapy in reducing the progression of fibrosis in a subject having fibrosis, methods of selecting a subject for participation in a clinical trial for the treatment of fibrosis, and methods for inhibiting progression of fibrosis in a cell or a subject having fibrosis. The methods are based on determining the level of Toll-like recepter 9 (TLR9).11-08-2012
20110300160SULFATION OF WNT PATHWAY PROTEINS - Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein lacking a sulfation site that is present in the native Wnt pathway protein is provided. Also provided is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided.12-08-2011
20100215668METHODS FOR THE TREATMENT OR PREVENTION OF HEMORRHAGIC CONDITIONS - The present invention relates to a method for treatment or prevention of a hemorrhagic condition in a patient by administering plasminogen activator inhibitor-1 (“PAI-1”) and/or an inhibitor of deubiquitinating enzyme CYLD (“CYLD”) to a patient. Pharmaceutical compositions that include one or both of PAI-1 and an inhibitor of CYLD are also disclosed.08-26-2010
20090214572Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders - The invention features methods and compositions for treating and preventing angiogenic disorders and endothelial cells disorders using HspA12B antagonist and HspA12B agonist compounds, respectively.08-27-2009
20130011416INJECTABLE SOLUTION CONTAINING THERAPEUTIC AGENT FOR OSTEOARTHRITIS - Injections for treating and preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, diseases classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or diseases classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix.01-10-2013
20130017209A-BETA BINDING POLYPEPTIDES - The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.01-17-2013
20110135661TREATMENT AND PREVENTION OF DRY AGE-RELATED MACULAR DEGENERATION BY ACTIVATING CD36 - The present invention relates to methods and compositions for the prevention and/or treatment of dry age-related macular degeneration by administering a CD 36-activator compound to a subject in need thereof; wherein the CD36 activator compound is the CD36 antibody FA6-152, or the growth hormone (GH)-releasing peptide family-derived compound EP80317 or the compound of Formula 1 [A-(Xaa)06-09-2011
20110159016HEMOGLOBIN-BASED METHODS FOR PROPHYLAXIS, DIAGNOSIS AND/OR TREATMENT OF RETINAL DISORDERS - The presently disclosed subject matter provides methods of diagnosing retinal disorders in subjects by measuring hemoglobin and modified hemoglobin in the subjects. The presently disclosed subject matter further provides methods of treating retinal disorders in subjects by decreasing hypoxia in retinal tissue of the subjects through modulation of hemoglobin levels and activities in the retinal tissue.06-30-2011
20110159015HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4 - A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.06-30-2011
20110159014ANTI-HER2 ANTIBODY VARIANTS - The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains06-30-2011
20110159013Anti-ADDL Antibodies and Uses Thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.06-30-2011
20110159012METHOD FOR ISOLATING NEURAL CELLS USING TENASCIN-R COMPOUNDS - The invention relates to a process for isolating neural cells using tenascin-R compounds, tenascin-R fragments and tenascin-R fusion proteins that are particularly suitable for such process, the recombinant preparation of such tenascin-R compounds, and a kit for performing this process, and the use of the process for preparing highly pure neural cell populations. The invention further relates to antibodies suitable for the detection and isolation of tenascin-R compounds.06-30-2011
20130022621ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS - The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.01-24-2013
20130022620ASSAYS AND METHODS PERTAINING TO PRE-AMYLOID INTERMEDIATES - The present invention relates to amyloidogenic peptides, polypeptides and proteins; and methods for screening to identify modulators of polypeptide self-aggregation into amyloids. The invention further relates to assays and methods using islet amyloid polypeptide (IAPP) as a component of a model system with which to screen for modulators of islet amyloid formation and accumulation. Also encompassed are modulators identified using the assays and methods described herein and compositions comprising same. The present invention also relates to methods and compositions for modulating amyloid formation and accumulation, thereby providing novel treatments for amyloidoses. In a particular aspect, methods and compositions are presented for inhibiting islet amyloid formation and accumulation, thereby providing novel treatments for diabetes.01-24-2013
20130022622COMPOUNDS FOR THE TREATMENT OF AUTISM - A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described.01-24-2013
20080241165Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fiber formation and modulating cross-beta structure-mediated toxicity - The invention relates to the field of biochemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structures and the biological role of these cross-β structures. In one embodiment, the invention discloses a method for modulating extracellular protein degradation and/or protein clearance comprising modulating cross-β(beta) structure formation (and/or cross-β structure-mediated activity) of the protein present in the circulation.10-02-2008
20080233134Antibodies That Specifically Bind to Chemokine Beta-4 - The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to CK-B4.09-25-2008
20080233133Humanized collagen antibodies and related methods - The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.09-25-2008
20080233132MULTIPLE SCLEROSIS THERAPY - The present invention relates to methods for treating multiple sclerosis by combining immunotherapy with myelin repair.09-25-2008
20090081239Humanized PAI-1 Antibodies - The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-03-26-2009
20080226655Kallikrein-Inhibitor Therapies - Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.09-18-2008
20110262457MODULATION OF THE IMMUNE RESPONSE - Methods for increasing the generation of IL-17-producing T cells (T10-27-2011
20130171171PROSTAGLANDIN TRANSPORTER INHIBITORS - The present invention generally relates to prostaglandin transport. More specifically, the invention is directed to compounds that inhibit prostaglandin transport and subsequent COX-2 induction, and methods relating thereto.07-04-2013
20130177575NOVEL THERAPEUTIC TARGET AND DIAGNOSTIC MARKER FOR ASTHMA AND RELATED CONDITIONS - CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression.07-11-2013
20130177576Compositions And Methods For The Treatment Of Neurologic And Psychiatric Conditions - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLCγ1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLCγ1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.07-11-2013
20130177574ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE - Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.07-11-2013
20130171170ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.07-04-2013
20130171172CALPAIN-3 INHIBITORS FOR TREATING MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES - A composition comprising a calpain-3 inhibitor for treating muscular dystrophies and cardiomyopathies, in particular tibial muscular dystrophy (TMD).07-04-2013
20080213286Mam Domain Containing Protein - This invention relates to a novel protein, termed INSP152, herein identified as a secreted protein, in particular, as a MAM domain containing protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment.09-04-2008
20110268748NURR-1 Interacting Protein (NuIP) - Provided herein are methods of promoting the activity of Nurr1 in a cell comprising contacting the cell with NuIP or an analog or fragment thereof. Also provided are methods of treating or preventing a condition associated with reduced dopaminergic function in a subject, comprising administering to the subject NuIP or an analog or fragment thereof. Methods of inhibiting the activity of Nurr1 in a cell comprising contacting the cell with a NuIP inhibitor are provided. Methods of screening for agents that modulate the interaction of Nurr1 and NuIP are also provided.11-03-2011
20110268747STXBP1 AS PSYCHIATRIC BIOMARKER IN MURINE MODEL SYSTEM AND THEIR USES - A non-human transgenic animal having a polynucleotide encoding an STXBP1 polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the STXBP1 polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illness are disclosed.11-03-2011
20090148464PREVENTIVE OR THERAPEUTIC AGENT CONTAINING ANTI THIOREDOXIN ANTIBODY POLYPEPTIDE AS AN ACTIVE INGREDIENT FOR DISORDERS - The present invention provides a preventive or therapeutic agent being effective for disorders induced by macrophage migration inhibitory factor and vascular system disorders, and having fewer side effects. In particular, the present agent is characterized by containing anti TRX antibody polypeptide as an active ingredient to inhibit adherence of leukocyte to vascular endothelial cell and a cell internalization of the macrophage migration inhibitory factor.06-11-2009
20130095116RSPO Binding Agents and Uses Thereof - The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.04-18-2013
20130095118Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability - Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.04-18-2013
20130095119COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.04-18-2013
20130115226METHODS AND USES OF TIE2 BINDING AND/OR ACTIVATING AGENTS - The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or chemokine levels.05-09-2013
20130115225REDUCER OF IMMUNOSUPPRESSION BY TUMOR CELL AND ANTITUMOR AGENT USING THE SAME - The invention features methods for inhibiting enhancement of expression of a FoxP3 gene in a cell, methods for inhibiting induction of differentiation of a cell into a regulatory T cell, methods for reducing immunosuppression, methods for stimulating tumor immunity, and methods for treating a patient with a tumor. The methods of the invention involve suppressing function of an FSTL1 protein in the cell. In the methods of the invention, function of an FSTL1 protein in the cell may be suppressed using an anti-FSTL1 antibody.05-09-2013
20130115227ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF - Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.05-09-2013
20130101606Novel Phosphorylation of Cardiac Troponin I as a Monitor for Cardiac Injury - This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.04-25-2013
20130101605MODULATORS AND MODULATION OF THE INTERACTION BETWEEN RGM AND NEOGENIN - This invention relates to drug screening using mammalian repulsive guidance molecules and mammalian Neogenin. In addition, the invention provides for methods of preventing, alleviating or treating various disorders of the nervous system, angiogenic disorders or disorders of the cardio-vascular system and malignancies of different etiology by disrupting the interaction between RGM and Neogenin.04-25-2013
20130177577NLRC5 AS A TARGET TO INTERVENE MHC CLASS 1-MEDIATED IMMUNE RESPONSES - A method to modulate MHC class I gene expression by modulating NLRC5 expression and/or NLRC5 activity in a subject is provided. The method comprises administering to the subject a compound HLA-A HLA-B that modulates NLRC5 expression and/or NLRC5 activity in an amount effective to modulates MHC class I gene expression. Also described is a screen for compounds that modulate NLRC5 expression. Candidate compounds are tested for their ability to modulate NLRC5 expression.07-11-2013
20130095117THERAPEUTIC USES OF INHIBITORS OF RTP801 - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.04-18-2013
20100278841DOWN-REGULATION OF MORTALIN BY siRNA - Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.11-04-2010
20110217316GBS Toxin Receptor Compositions and Methods of Use - Methods are provided for preventing or attenuating pathoangiogenic conditions by administering at least one GBS toxin receptor polypeptide or at least one immunogenic fragment thereof. Also provided are a composition that includes a GBS toxin receptor polypeptide and a method for making such a composition. In another embodiment of the invention, immunized animals also receive GBS toxin, immunocompatible antibodies to the GBS toxin receptor, and/or expanded autologous T cells to the GBS toxin receptor. Also included in this invention are methods of identifying additional GBS toxin receptors.09-08-2011
20110217315METHODS AND COMPOSITIONS FOR RISK PREDICTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF PULMONARY DISORDERS - The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease.09-08-2011
20110229492COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING PROSTATE CONDITIONS - Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).09-22-2011
20110243963ANTIBODIES TO LRP6 - Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing.10-06-2011
20130149317MALARIA VACCINE - The present invention relates to a malaria vaccine comprising:06-13-2013
20130149316Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.06-13-2013
20130149315ANTIBODIES AGAINST GLUCAGON RECEPTOR AND THEIR USE - Disclosed are immunological compositions and methods for reducing activity of glucagon signaling using antibodies against glucagon receptor.06-13-2013
20120276121USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES - The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.11-01-2012
20120276120T-Cell Stimulating Protein B and Methods of Use - Polypeptides that can elicit antibodies that bind to T-cell stimulating protein B (TspB) of 11-01-2012
20120276119CD37-Binding Molecules and Immunoconjugates Thereof - Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.11-01-2012
20120276118HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I11-01-2012
20120276117Binding Partners for the Thyrotropin Receptor and Uses Thereof - A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.11-01-2012
20120276116Prevention and Treatment of Amyloidogenic Disease - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto.11-01-2012
20100291106COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B - The present invention relates to antibodies and antigen binding fragments thereof that bind to both human and cynomolgus complement protein C3b, as well as compositions and methods of use thereof.11-18-2010
20100310580COMPOSITIONS AND METHODS FOR TREATING PRURITUS - The present invention encompasses methods and compositions for alleviating pruritis. The compositions may comprise an analgesic agent.12-09-2010
20110274703DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS - The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.11-10-2011
20130156792Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.06-20-2013
20130156793INSULIN-RESISTANCE-IMPROVING DRUG - Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of FSTL3. Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3.06-20-2013
20130183319FGFR4 ANTIBODIES - The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.07-18-2013
20130183321GITR BINDING MOLECULES AND USES THEREFOR - The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.07-18-2013
20110293635COMPOSITION AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR ACTIVITY - The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression of Toll-like Receptor 14 interaction with CD14 during Toll-like Receptor mediated signalling. The invention further provides screening assays to identify compounds which have utility in preventing the association of Toll-like Receptor 14 and CD14.12-01-2011
20110311554Compositions and Methods for Suppressing Fibrocytes - The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.12-22-2011
20110311553Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation - The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.12-22-2011
20110311552NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF - Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of treating cancer comprising administering said antibody to a subject.12-22-2011
20130189281ANTIBODIES THAT BIND PAR-2 - The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.07-25-2013
20130189282METHODS FOR ISOLATING AND USING A SUBSET OF CD8 T-CELLS THAT ARE RESISTANT TO CYCLOSPORIN - Utilizing a novel T cell culture system based on allogeneic epithelial antigen presenting cells (semi-professional APC), a cyclosporin-resistant CD8 T cell clone with minimal cytolytic capability was isolated. Derivation of the novel alloantigen-specific CD8 T cell clones involved previous priming with an allogeneic skin graft, implying expansion of this T cell subset during transplant rejection. Characterization and comparison of the cyclosporin and rapamycin-resistant CD 8 T cell clone with typical cyclosporin-sensitive CD 8 T cells suggests that it is a member of a CD8 T cell subset with a unique cell surface phenotype and novel TCR activation pathways, and that these unique CD8 T cell clones reflect the immunobiology of chronic rejection within the non-hematopoetic microenvironments of solid organs and vascular walls. These cells express the aryl-hydrocarbon receptor. T-cells of this type are referred to herein as CD8bm12-1 T-cells.07-25-2013
20130189283CARRIER IMMUNOGLOBULINS AND USES THEREOF - Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.07-25-2013
20120003244METHODS FOR APCDD1 MEDIATED REGULATION OF HAIR GROWTH AND PIGMENTATION AND MUTANTS THEREOF - The invention provides for methods for controlling hair growth by administering an APCDD1 modulating compound to a subject. The invention further provides for a method for screening compounds that bind to and modulate APCDD1.01-05-2012
20120020988Antibodies specifically binding to human TSLPR and methods of use - An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases.01-26-2012
20120020987MHC-Less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.01-26-2012
20120027778Frizzled-Binding Agents and Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.02-02-2012
20130195894DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS - Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.08-01-2013
20130195895METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION - The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.08-01-2013
20130202622METHOD FOR THE TREATMENT OF OBESITY - The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.08-08-2013
20130202619METHODS AND MATERIALS FOR REDUCING LIVER FIBROSIS - This document relates to methods and materials for treating diseases or disorders that are caused by or associated with lumican deposition (e.g., liver fibrosis). For example, methods and materials for reducing liver fibrosis by reducing lumican expression or activity within a mammal (e.g., a human) are provided.08-08-2013
20130202620HIGH CONCENTRATION ANTIBODY FORMULATIONS - Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.08-08-2013
20130202621Antibodies Directed To Alpha V Beta 6 And Uses Thereof - Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.08-08-2013
20120064094Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders - The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder.03-15-2012
20120301486COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.11-29-2012
20130095120ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY - The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.04-18-2013
20120093836PHARMACEUTICAL COMPOSITIONS FOR TREATING METASTASIS - The present invention relates to the use of an antifungal agent or of a compound capable of binding to a mannoprotein and blocking the binding of said mannoprotein to an endothelial cell receptor, in the preparation of a pharmaceutical composition for treating a disease associated to an unwanted cell adhesion. Likewise, the present invention also contemplates methods aimed at identifying a compound potentially useful for preventing and/or treating a disease associated to an unwanted cell adhesion, for predicting the probability of a patient suffering from cancer to suffer from metastasis and for designing a personalized therapy for a patient suffering from cancer.04-19-2012
20120093835ANTI-INFLAMMATORY ANTIBODIES AND USES THEREFOR - The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders.04-19-2012
20130209492Anti-Tie2 Antibodies and Uses Thereof - The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.08-15-2013